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ABSTRACT 
An estimated 34 million people worldwide are infected with human 
immunodeficiency virus (HIV). Understanding how the immune system reacts to HIV 
infection and why normal antiviral defenses are insufficient to fight infection is a key step 
towards creating better therapies. Several interferon-induced proteins, such as the 
tripartite motif protein TRIM22, are capable of restricting HIV-1 replication in vitro; 
however the contribution of these antiviral factors to HIV-1 pathogenesis is unclear. 
Previous studies have observed that single nucleotide polymorphisms (SNPs) can 
dramatically impact the actions of these proteins and influence the severity of HIV-1 
infection. While numerous SNPs have been reported in the trim22 gene, no study has 
addressed how these may affect TRIM22 functions. Here we used U2OS cells to provide 
the first direct comparison of two TRIM22 isoforms. Through confocal microscopy we 
observed these isoforms to exhibit different patterns of localization, was dependent on the 
TRIM22 B30.2 domain. In vitro studies revealed that both isoforms restricted release of 
infectious HIV-1 particles, though to different extents. Furthermore, both isoforms 
restricted transcription from the HIV-1 and cytomegalovirus promoters to varying 
degrees, as determined by qRT-PCR analysis. Collectively, these data suggest that 
TRIM22 antiviral activity is variable between isoforms, and that SNPs may alter its 
biological characteristics. 
KEYWORDS 
Human immunodeficiency virus, TRIM22, tripartite motif proteins, antiviral, innate 
immunity, interferon, restriction factor, single nucleotide polymorphism 
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CHAPTER 1: INTRODUCTION 
1.1 Human Immunodeficiency Virus Type 1 
Human immunodeficiency virus type 1 (HIV-1) is a retrovirus that primarily 
infects CD4+ T lymphocytes (T cells), leading to gradual destruction of the immune 
system and the eventual progression to Acquired Immune Deficiency Syndrome (AIDS). 
The HIV-1 genome is approximately 9.7 kilobase pairs in length, and is composed of 9 
genes that are flanked by two long terminal repeats (LTR) (Figure 1). The HIV-1 LTRs 
have central roles in integration of the viral genome into the host cell genome, and 
subsequent transcription of the integrated viral genes. The gag, pol, and env genes are 
conserved among all retroviruses, and code for structural proteins, enzymes, and 
envelope glycoproteins, respectively. Two regulatory proteins, Tat and Rev, also have 
significant roles in HIV replication. Tat is important for efficient transcription from the 5‟ 
LTR and Rev is required for the transport of viral RNAs from the nucleus to the 
cytoplasm. Finally, HIV-1 encodes 4 accessory proteins: Vif, Vpu, Vpr, and Nef. These 
proteins are not essential for in vitro replication; however they possess a range of 
important and interesting functions for productive infections, such as immune evasion 
and counter-measures (reviewed in [1, 2]). 
1.1.1 HIV-1 lifecycle 
The HIV-1 lifecycle can be divided into early and late stages (Figure 2). In the 
early stages, infection begins with adsorption of mature virions to CD4 receptors on the 
target cell, which is mediated through the HIV surface glycoprotein gp120. Entry also 
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Figure 1: Schematic of the HIV-1 genome. 
The HIV-1 genome is approximately 9.7 kilobase pairs (kb) in length, and encodes 9 
genes. Three genes (gag, pol, env) are common among all retroviruses, and are 
synthesized as polyprotein precursors. HIV-1 also encodes 6 accessory proteins (tat, rev, 
vif, vpr, vpu, nef), which are the primary translation products of spliced mRNA. Two of 
these genes (tat and rev) contain spliced exons, as indicated by the dotted black lines. 
Two long terminal repeats (LTR) boarder the genome, and have roles in integration, 
replication, and transcription. 
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requires binding to a chemokine co-receptor, which also determines viral tropism, and 
which cell types it can infect. The two most common co-receptors are CCR5 and 
CXCR4. CCR5 is expressed by macrophages and primary lymphocytes, and is important 
during early stages of infection, such as HIV-1 transmission (reviewed in [1-3]). This 
observation is highlighted by the resistance to HIV-1 infection in individuals 
homozygous for the CCR5/Δ32 mutation, which encodes a non-functional CCR5 co-
receptor [4-6]. Although CXCR4 is also expressed by primary lymphocytes, in many 
patients the emergence of CXCR4- and dual-tropic (CXCR4 and CCR5) viral variants are 
not observed until late stages of infection, typically around the onset of AIDS [7]. 
Binding of gp120 induces conformational changes in the HIV transmembrane protein 
gp41, which in turn mediates fusion of the viral and host cell membranes [8]. Upon 
capsid uncoating, several viral proteins remain associated with the negative-sense ssRNA 
genome, including matrix and nucleocapsid structural components, the reverse 
transcriptase and integrase enzymes, and Vpu. These proteins form the reverse 
transcription complex and mediate reverse transcription of the genome into dsDNA. 
From here the newly synthesized DNA associates with several viral and host proteins, 
forming the preintegration complex, which is subsequently imported into the nucleus. 
Once in the nucleus the viral integrase protein mediates integration of the viral dsDNA 
into the host cell genome, completing the early stages of HIV-1 infection (reviewed in [1, 
2]). 
Late stages of the viral lifecycle begin with transcription of viral genes. 
Transcription of the integrated provirus is directed from the viral 5‟ LTR, which contains 
several promoter and regulatory elements, and requires both host and viral proteins 
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Figure 2: Schematic outline of the HIV-1 lifecycle. 
Infection begins with adsorption of mature viral particles to the host cell (primarily CD4+ 
T cells), mediated through binding of the viral envelope protein to a cellular CD4 
receptor and chemokine co-receptor (most often CXCR4 or CCR5). Viral and cell 
membranes fuse, releasing the virus capsid into the cytoplasm.  The capsid is broken 
down (uncoating), releasing the viral genome, two single strands of negative sense RNA, 
and associated proteins (i.e. reverse transcriptase and integrase). The RNA is reversed 
transcribed into double stranded cDNA, which is transported into the nucleus as part of 
the pre-integration complex, and integrated into the host genomic DNA. Stages up to and 
including integration encompass the early stages of the HIV-1 lifecycle. Late stages of 
the HIV-1 lifecycle begin with transcription of the integrated viral DNA, which is 
directed from the HIV-1 5‟ long terminal repeat (LTR) and enhanced by the viral Tat 
protein. Viral messenger RNAs (mRNA), some of which are spliced, are exported into 
the cytoplasm in a manner dependent on the viral Rev protein, and translated into viral 
proteins. Envelope proteins are transported from the Golgi complex to the cell surface, 
where they embed in the plasma membrane. Gag polyproteins, some associated with 
genomic RNA, are targeted to the membrane where they oligomerize and direct budding 
of nascent particles through the membrane. After release, the Gag polyprotein is 
subsequently cleaved into its domains (matrix, capsid, nucleocapsid and p6) by the 
virion-encoded protease. This allows structural and morphologic rearrangement, such as 
condensation of the core into a cone-shaped structure, and generates mature, infectious 
particles. 
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(reviewed in [9]). The core promoter contains a TATA element, and three tandem Sp1 
binding sites which are critical to viral transcription [10, 11]. Upstream of the core 
promoter is the enhancer, which contains binding sites for three transcription factors 
(NFκB, NFAT, AP-1) that are involved in viral transcription in T lymphocytes following 
activation [12-14]. The NFκB binding motif is conserved in all HIV-1 isolates, and is 
vital to viral transcription [15-17]. Likewise, the HIV-1 Trans-Activator of Transcription 
protein (Tat) is indispensible for HIV-1 infection, and enhances LTR-directed 
transcription by hundreds to thousands fold [18, 19]. Tat functions by binding the TAR 
element, a secondary RNA structure formed by the 5‟ end of all nascent HIV-1 
transcripts. Once bound, Tat is involved in recruiting cellular cofactors and stabilizing 
RNA polymerase II [20]. Notably, without a functional Tat protein, transcripts are 
randomly and prematurely terminated, and progeny virions are not produced [18, 19]. 
Nascent viral transcripts are exported from the nucleus via the viral Rev protein, 
and are translated in the cytoplasm using normal host machinery. Envelope glycoproteins 
are targeted to, and assemble on the outside of the host cell membrane, awaiting viral 
assembly – a process that is driven via the Gag polyprotein (Pr55Gag). Interestingly, 
expression of Gag alone is sufficient for the formation of noninfectious virus-like 
particles (VLPs) [21]. Pr55Gag contains four major domains, each of which have 
important roles in HIV assembly and release. In brief, the N-terminal matrix domain 
targets Pr55Gag to the site of assembly at the plasma membrane, the capsid domain 
facilitates multimerization of Pr55Gag polyproteins, the nucleocapsid domain binds the 
ssRNA genome, and the p6 domain recruits cellular proteins important for budding and 
release (reviewed in [22-24]). Upon release the viral protease cleaves the Pr55Gag 
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polyprotein into its respective domains, forming the structural components of the HIV 
virion [25]. This process is called maturation, and is the final step in creating infectious 
HIV particles [26]. 
1.2 The interferon response 
The interferon (IFN) system is a key mediator of the innate immune response, and 
the first line of defense against viral infections. IFNs are a class of cytokines produced 
and secreted in response to external stimuli, such as viral infection, and signal 
neighbouring cells to initiate an antiviral state. The three major types of IFNs (type I-III) 
are differentiated based on the receptors they bind (Figure 3), with each type also having 
slightly different sets of functions. Type I IFNs (α, β, ε, κ, ω) are indispensible for 
defence against many viruses, and the two main subtypes, IFN-α and IFN-β, are produced 
by almost every cell in the body. All type I IFNs signal through a common, ubiquitously 
expressed interferon alpha receptor (IFNAR) – a heterodimeric receptor composed of the 
IFNAR1 and IFNAR2 subunits. Similarly, type II IFN (IFN-ɣ) bind to an interferon 
gamma receptor (IFNGR) composed of the IFNGR1 and IFNGR2 subunits. In contrast to 
type I IFNs, type II IFNs have a larger role in immune regulation as opposed to direct 
antiviral actions, and is primarily released by immune cells, such as NK or effector T 
cells (reviewed in [27-31]. Type III IFNs (IFN-λ) signal through a third heterodimeric 
receptor, which is composed of an IFNλR1 chain and an IL-10R2 chain, and is primarily 
expressed on epithelial cells. Although type III IFN is a relatively new and distinct 
member of the IFN family, it appears to share many similarities to type I IFNs, including 
expression patterns, induction mechanisms, and biological activities (reviewed in [28-
31]).
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Figure 3: Schematic of interferon signaling pathways and induction of ISGs. 
The three major types of IFNs (type I-III) are separated based on the receptors they bind. 
Type I IFNs (α, β) signal through the interferon alpha receptor (IFNAR), composed of the 
IFNAR1 and IFNAR2 subunits. Type III IFNs (IFN-λ) bind a heterodimeric receptor 
composed of an IFNλR1 chain and an IL-10R2 chain. Both type I and III IFN receptors 
associate with the Tyk2 and Jak1 kinases, resulting in the tyrosine phosphorylation and 
activation of STAT2 and STAT1. STAT1 and STAT2 combine with IFN regulatory 
factor 9 (IRF-9) to form the transcription factor complex IFN stimulated gene factor 3 
(ISGF3), which translocates to the nucleus and interacts with IFN-stimulated response 
elements (ISRE) to regulate transcription of interferon stimulated genes (ISGs). In 
contrast, type II IFN (IFN-ɣ) binds as a dimer to the interferon gamma receptor (IFNGR) 
composed of two IFNGR1 and IFNGR2 subunits. The IFNGR1 and IFNGR2 receptors 
associate with Jak1 and Jak2 and result in the phosphorylation and activation of STAT1 
alone. STAT1 homodimers translocate to the nucleus and are capable of binding 
alternative promoter elements, such as gamma activated sites (GAS), and regulating 
transcription of other IFN-responsive genes. 
10 
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Binding of IFNs to their associated receptors activates a Janus Kinases/Signal 
Transducers and Activators of Transcription (Jak/STAT) signalling cascade that 
ultimately results in the upregulation of a vast array of interferon stimulated genes (ISGs) 
(Figure 3). Both type I and III IFN receptors associate with the Tyk2 and Jak1 kinases 
through the IFNAR1/IL-10R2 and IFNAR2/IFNλR1 receptor subunits, respectively. This 
association results in the tyrosine phosphorylation and activation of STAT2 and STAT1, 
which together with IFN regulatory factor 9 (IRF-9), form the transcription factor 
complex IFN stimulated gene factor 3 (ISGF3). Upon formation, ISGF3 translocates to 
the nucleus and regulates transcription though binding to IFN-stimulated response 
elements present in the promoters of certain ISGs. Alternatively, the IFNGR1 and 
IFNGR2 receptors associate with Jak1 and Jak2, respectively, leading to the 
phosphorylation and activation of STAT1 alone. In addition, all IFN signalling pathways 
can lead to the formation of STAT1–STAT1 homodimers capable of binding alternative 
promoter elements (Gamma activated sites) and regulating transcription of other IFN-
responsive genes (reviewed in [27-31]. 
Many interferon-induced proteins, termed cellular restriction factors, have been 
identified to have specific antiviral functions that target various stages of the viral 
lifecycle. For instance, the ubiquitin-like molecule ISG15 is noted to be one of the most 
upregulated genes in response to IFN. Interestingly, several proteins with important roles 
in the type I IFN response have been identified as putative targets for modification with 
ISG15 (termed ISGylation) [32]. ISG15 has also been reported to help prevent viral 
counteraction of the IFNβ response [33], to possess immune modulatory capabilities [34], 
and several studies in mice have shown that ISG15 deficiency corresponds to increased 
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susceptibility to multiple viruses (reviewed in [31]). Furthermore, ISG15 has been shown 
to restrict the replication of a range of viruses [35-42], including Influenza A [35-38], 
Ebola [40], and HIV-1 [41, 42]. 
Similarly, other well-known IFN-induced antiviral proteins, such as Protein 
Kinase R (PKR) and 2´,5´-oligoadenylatesynthetase 1 (OAS1)/RNaseL, are expressed at 
basal levels in addition to being highly upregulated in response to IFN, allowing them to 
serve as both viral sensors and antiviral effectors. These proteins sense viral infection and 
are activated by the presence of dsRNA, which is not normally present in uninfected 
cells. This activation signals inactive OAS1 monomers to oligomerize and synthesize 
2‟,5‟-oligoadenylates, which in turn activate RNaseL, a ribonuclease that degrades viral 
and cellular RNA. Similarly, activation of PKR results in the dimerization of inactive 
monomers, forming a functional protein capable of inhibiting translation (reviewed in 
[31, 43, 44]). Interestingly, both of these proteins have been shown to be activated by, 
and to possess antiviral activity against HIV-1 infection [45-48]. 
Not surprisingly, the actions of type I IFNs on HIV-1 replication have been 
extensively studied. Type I IFN treatment of cells in vitro interrupts both early [49-51] 
and late stages of the viral lifecycle [52-55]. The use of type I IFN to treat HIV-1 patients 
has also had success [56-60], but has come under scrutiny due to adverse effects [61]. 
Similarly, antiretroviral drugs have failed to provide a cure due to the emergence of drug-
resistant strains [62] and toxicity-induced patient noncompliance [63]. In addition, an 
effective HIV-1 vaccine has yet to come to fruition (reviewed in [64]). In an attempt to 
develop new strategies against HIV infection, much research has been conducted on the 
mechanisms of action for different cellular HIV-1 restriction factors (reviewed in [43]). 
13 
 
 
 
1.3 HIV-1 restriction factors 
1.3.1 APOBEC3 
One of the best characterized HIV-1 restriction factor families is the human 
apolipoprotein B mRNA-editing catalytic polypeptide-like 3 (APOBEC3) family. There 
are seven members of APOBEC3 proteins (A-H), all of which are cytidine deaminases 
capable of converting cytosine to uracil in RNA or DNA, and all have some degree of 
activity to mutate and restrict HIV-1 (reviewed in [65]). APOBEC3G (A3G) was the first 
member identified to block HIV-1 infection, and also appears to be the most potent 
family member against HIV-1 [66]. In the absence of HIV-1 Vif, A3G is packaged into 
newly formed virions and subsequently imparts its antiviral action upon infection of a 
new cell. During reverse transcription, A3G induces cytidine deamination (C→U 
mutations) in the negative strand of newly synthesized viral cDNA. This results in G→A 
hyper-mutation of the viral genome, and consequently the possibility for the production 
of premature stop codons or mutated, non-functional viral proteins [67-74]. In addition, 
A3G is known to function in a deaminase-independent manner by interfering with reverse 
transcription [75-78], and has been linked to decreased accumulation of viral cDNA [74, 
79-84]. Nevertheless, HIV-1 possesses an A3G counter-measure in the Vif protein, which 
is capable of restoring infectivity by inducing the degradation of multiple APOBEC3 
proteins [70, 85-89]. 
1.3.2 Tetherin 
In contrast to APOBECs, the restriction factor tetherin (Bone Marrow Stromal 
Cell Antigen 2; CD317) blocks late stages of HIV-1 replication [90]. Tetherin is a 
transmembrane protein capable of binding the host cell and viral membranes during the 
14 
 
 
 
viral assembly/release stage. Binding results in the accumulation of HIV-1 particles at the 
cell membrane in a chain-like fashion [91], and ultimately induces the reinternalization of 
released particles and their subsequent degradation within the cell [92]. Although the 
exact mechanisms behind tetherin-mediated restriction are still unclear, certain aspects 
have been elucidated, including the fact that dimerization of tetherin is required for HIV-
1 restriction [93]. Nevertheless, HIV-1 also encodes a tetherin counter-measure in the vpu 
gene, limiting tetherin‟s effectiveness to HIVΔVpu strains [90]. Similar to Vif-induced 
degradation of A3G, the Vpu protein is capable of targeting tetherin for degradation, 
restoring effective release of mature HIV-1 virions from the host cell [90, 94]. The details 
of Vpu-mediated degradation are still uncharacterized, however two major hypotheses 
currently exist. One theory involves the post-translational ubiquitination of tetherin [95-
97], leading to subsequent endocytosis from the cell membrane and degradation [92, 94, 
98]. The second theory states that tetherin trafficking to the plasma membrane is blocked, 
and is instead delivered to late endosomal compartments [99, 100]. 
1.4 Tripartite Motif (TRIM) Proteins 
Some restriction factors, such as members of the Tripartite Motif (TRIM) family 
(TRIM5α and TRIM22), can target multiple stages of the HIV-1 lifecycle. The TRIM 
family is a class of innate immune proteins with widespread antiviral activity. There are 
currently 75 identified members, all containing a highly conserved “RBCC” motif (RING 
domain, one or two B-box domains, and a predicted Coiled-Coil region) (reviewed in 
[101]) (Figure 4). The N-terminal RING (Really interesting new gene) domain contains a 
specialized zinc finger that coordinates two zinc atoms, and many RING proteins have 
been shown to have E3 ubiquitin ligase activity [102, 103]. Considerably less is known 
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about the other domains of TRIM proteins. The B-box domain is unique to TRIM 
proteins and also contains a zinc finger. Although the function of these domains is not yet 
known, the B-box 2 of TRIM5α is important in forming higher-order associations among 
TRIM5α oligomers, and mutations result in reduced binding to the HIV-1 capsid protein 
[104]. The B-box domain is followed by a predicted coiled-coil region, which is believed 
to be involved in oligomerization of at least some TRIM proteins, such as TRIM22 [105]. 
The RBCC motif is often followed by a C-terminal domain, which for 60% of TRIM 
proteins, including TRIM22, is a B30.2/SPRY domain [101]. Although the exact function 
of the SPRY domain is still unclear, it is believed to be involved in RNA binding [106] 
and/or protein-protein interaction [107]. This domain also appears to have essential links 
to antiviral activity, as observed in studies of HIV-1 restriction by TRIM5α [108]. 
1.4.1 TRIM5α 
TRIM5α is the earliest acting HIV-1 restriction factor currently known. Before 
TRIM5α was identified as an HIV-1 restriction factor, it was observed that HIV-1 could 
enter the cells of Old World monkeys, such as the rhesus macaque; however the virus 
was blocked from producing a productive infection [109-111]. This introduced the idea 
of species-specific restriction of HIV-1 replication, and from here it was discovered that 
the rhesus macaque TRIM5α (RhTRIM5α) was capable of potently restricting HIV-1 
replication [112]. Further research has indicated that restriction is believed to be due to 
specific recognition of the HIV-1 capsid protein through the C-terminal B30.2 domain of 
RhTRIM5α, resulting in premature disassembly of the capsid during infection [113]. In 
addition, RhTRIM5α appears to interfere with HIV-1 reverse transcription and nuclear 
import of the viral cDNA [114-116]. Although controversial, RhTRIM5α also blocks late 
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Figure 4: Schematic representation of TRIM22 isoforms used in literature. 
All tripartite motif (TRIM) proteins contain a highly conserved “RBCC” (Ring, one or 
two B-Boxs, Coiled-Coil) motif, followed by a C-terminal domain, the most common of 
which is the B30.2/SPRY domain. The start/end amino acid positions of each domain are 
indicated below each isoform. The locations of SNPs are reported in relation to the 
TRIM22β/BC035582 sequence, and are depicted by yellow bands. The bi-partite and 
„KRK‟ nuclear localization signals (NLS) located at amino acids 257/265 and 380 are 
depicted by purple and blue bands, respectively. A) TRIM22β is commercially available, 
and matches the consensus sequence for trim22. B) HQ_842635 was cloned from U937 
cells, and contains SNPs at nucleotides 463 and 725, resulting in two amino substitutions: 
D155N, and R242T. C) The first trim22 clone, X82200, was created from a splice variant 
missing nucleotides 519-531, resulting in a 4 amino acid deletion from the coiled-coil 
domain. It contains an SNP at nucleotide 725, resulting in the R242T substitution. A 
single nucleotide deletion at nucleotide 1316 causes a frameshift mutation and the 
production of a premature stop codon at nucleotide 1326. The resulting protein is 442 
amino acids, and contains the unique C-terminal sequence „LPVVLGFS‟. D) TRIM22α 
was cloned using primers based on X82200. It also lack nucleotides 519-531, and 
contains the R242T substitution, however there is no deletion at nucleotide 1316. As a 
result, there is no premature stop codon at nucleotide 1326, and the clone runs 18 
nucleotides into the pcDNA3.1 backbone, creating the unique C-terminal sequence 
„ARACI‟. 
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stages of HIV-1 infection by targeting the Gag polyprotein for degradation and 
interfering with viral assembly [117-119]. Interestingly, the human TRIM5α homologue 
(HuTRIM5α) possesses little to no antiviral activity against HIV-1 replication [112]. 
Furthermore, the lack of restriction by HuTRIM5α has been mapped to a single amino 
acid mutation (R332P) in the B30.2 domain [108], and restoration of a proline at this 
position restores capsid binding capabilities and greatly improves HIV-1 restriction by 
HuTRIM5α [120]. 
1.4.2 TRIM22 
Human TRIM22 (also known as Stimulated trans-acting factor 50, Staf-50) was 
originally isolated in 1995 during a search for IFN-induced genes in Daudi cells, a well 
characterized B lymphoblast cell line [121]. The trim22 gene is located at chromosomal 
position 11p15, immediately adjacent to the TRIM5α gene [122]. TRIM22, along with 
TRIM5α, have been under positive selection episodically for approximately 23 million 
years; however these two genes have evolved in a mutually exclusive manner, with only 
one being selected for in a given primate lineage [123]. Although relatively little is 
known about the function of TRIM22 within the cell, it may play a role in cellular 
processes such as cell differentiation/proliferation [124, 125], and in diseases such as 
Wilms tumor [126, 127] and systemic lupus erythematosus [128]. TRIM22 is 
constitutively expressed in resting T cells [129], is a known p53 target gene [124] and 
NFκB activator [130], and is upregulated in response to type I and II IFNs [121, 122, 125, 
131-136]. In addition, its expression is altered in response to a variety of stimuli, 
including T-cell activation/co-stimulation [129, 135], multiple cytokines [135, 137], and 
multiple viral antigens/infections [138-143]. Furthermore, TRIM22 has been shown to 
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have antiviral activity against HIV-1 [131, 134, 144, 145], Hepatitis B virus (HBV) 
[132], and encephalomyocarditis virus [146]. 
1.5 TRIM22 inhibits HIV-1 Replication 
Despite being identified as a potential HIV-1 restriction factor over a decade ago, 
relatively little is known about the effect of TRIM22 on HIV-1 replication. TRIM22 was 
first discovered by Tissot and Mechti in 1995 during a search for IFN-induced genes in 
Daudi cells [121]. It was also noted that TRIM22 displayed high homology to the mouse 
Rpt-1 gene, which had previously been shown to down-regulate expression from the 
HIV-1 LTR [147]. Similarly, exogenous expression of TRIM22 was observed to down-
regulate transcription from the HIV-1 LTR in the COS7 cell lines [121]. Although this 
was performed using a luciferase reporter gene under the control of the LTR as opposed 
to an HIV-1 proviral genome, it provided the first evidence suggesting that TRIM22 may 
block HIV-1 transcription and ultimately replication. 
In 2006, TRIM22 was shown to be highly upregulated in primary monocyte-
derived macrophage (MDM) in response to HIV-1 infection or IFNα treatment. 
Exogenous expression of TRIM22 was subsequently shown to inhibit HIV-1 infection up 
to 50% in 293T cells modified to express the CD4 and CCR5 receptors. Furthermore, co-
transfection of TRIM22 with plasmids encoding a lentiviral packaging system based on 
the HIV-1 structure (M107, pMD-G and pCMV-ΔR8.9) resulted in reduced titres of 
pseudotyped virus compared to an empty vector control. Interestingly, in this 
pseudotyped virus system, expression of HIV-1 genes is directed from a cytomegalovirus 
(CMV) promoter (pCMV-ΔR8.9) as opposed to an actual HIV-1 LTR [131]. Since 
TRIM22 has been shown not to restrict transcription from the CMV promoter in 293T 
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cells [144], it serves to show that the potent restriction observed in 293T cells must be a 
result of TRIM22 acting at a separate late stage of the HIV-1 lifecycle. In addition, the 
over-expression of TRIM22 in primary MDM was also shown to restrict HIV-1 infection 
by 70-90%, and was capable of preventing the formation of syncytia [131]. Together, 
these experiments provided the first evidence that TRIM22 can restrict HIV-1 replication 
in vitro, and suggested that TRIM22 may possess transcription-independent antiviral 
activity. 
In 2008, Barr, et al. provided the first mechanistic data linking TRIM22 to 
restriction of HIV-1 replication. TRIM22 was shown to be highly upregulated in response 
to IFNβ treatment of HOS cells modified to express the CD4 and CXCR4 receptors 
(HOS-CD4/CXCR4). These cells support robust HIV-1 replication, which can be 
attenuated by IFNβ. Moreover, TRIM22 was shown to be an integral part of the IFNβ 
response against HIV-1 infection, noting that IFNβ-induced restriction of HIV-1 
replication was abolished after shRNA knockdown of TRIM22. In addition, exogenous 
over-expression of TRIM22 was shown to inhibit HIV-1 replication in several other cell 
lines. Interestingly, in the HOS and HeLa cell lines, TRIM22 expression repressed 
release of HIV-1 particles into the supernatant, but had no effect on the intracellular 
levels of HIV-1 Gag. Conversely, in the U2OS and 143b cell lines, both the release of 
HIV-1 particles into the supernatant as well as intracellular levels of Gag were decreased 
in the presence of TRIM22 [134]. 
Restriction in HOS-CD4/CXCR4 cells also appeared to be independent of any 
effect on the HIV-1 LTR, as TRIM22 was also shown to restrict the release of virus-like 
particles containing only the Gag protein expressed from the CMV promoter. 
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Furthermore, this restriction was determined to be a result of altered Gag trafficking to 
the plasma membrane. Although no mechanism of action was ever studied in U2OS or 
143b cells, several possibilities could explain the observed decrease of intracellular Gag, 
including inhibition of transcription or degradation of the Gag polyprotein. It is notable 
that the antiviral actions of TRIM22 were E3 ligase-dependent, and TRIM22 was shown 
to interact with HIV-1 Gag specifically [134]. This could suggest that TRIM22 mediates 
the ubiquitination of Gag, resulting in altered trafficking or proteasomal degradation, 
depending on the position and number of ubiquitin molecules [148]. Nevertheless, 
TRIM22 appears to have several distinct activities depending on the cell-line being used 
for investigation. 
It appears that TRIM22 is capable of restricting HIV-1 replication through at least 
two mechanisms: by targeting trafficking of the Gag polyprotein to the plasma 
membrane, as well as by down-regulating transcription from the HIV-1 LTR. 
Interestingly, clones of the U937 promonocytic cell line have been previously described 
as either permissive or nonpermissive, based on their efficient or inefficient support of 
HIV-1 replication [149]. Investigation of these clones revealed that trim22 expression 
could only be detected in nonpermissive clones, whereas other IFN-induced restriction 
factors were readily detected in both subsets. In addition, use of a luciferase reporter 
plasmid under the control of the HIV-1 LTR revealed that LTR-mediated transcription 
was decreased 7-10 fold in nonpermissive clones, which was recoverable to levels 
observed in permissive cells via shRNA knockdown of trim22 expression. Furthermore, 
exogenous expression of TRIM22 in permissive clones resulted in decreased LTR 
transcription comparable to that observed in nonpermissive clones. Similar results were 
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observed in the A3.01 T cell line, further supporting the effects of TRIM22 on HIV-1 
infection in critical cell targets [144]. 
The first clinically relevant evidence to support a role for TRIM22 as an anti-HIV 
effector in vivo was provided in 2011. A study monitoring gene expression in high-risk 
HIV-1 negative individuals detected a positive correlation between TRIM22 expression 
and increased control of HIV-1 infection. It was observed that IFNβ and TRIM22 levels 
in peripheral blood mononuclear cells (PBMCs) were increased in patients after HIV-1 
infection. In addition, infected patients expressing higher TRIM22 levels exhibited 
significantly lower viral loads and significantly higher CD4+ T cell counts, suggesting 
that TRIM22 may play a role in controlling HIV-1 infection. Furthermore, knockdown of 
TRIM22 in the Jurkat T cell line resulted in increased HIV-1 particle release and 
replication in vitro. Surprisingly, a significant inverse correlation was observed between 
the closely related IFN-inducible TRIM5α protein and IFNβ expression [145]. 
Nevertheless, these results suggest that human TRIM22 may be an important protein in 
controlling HIV-1 and/or other retrovirus infections, and additional studies will be 
required to determine the prevalence of TRIM22 forms and their relation to antiviral 
capability in vivo. 
1.6 Rationale for studying innate viral restriction factors 
As of 2010, the World Health Organization estimates that approximately 34 
million people worldwide are infected with HIV. Although the majority of infected 
individuals eventually progress to AIDS, especially in the absence of highly active anti-
retroviral therapy (HAART), a small percentage appear to possess levels of natural 
resistance to infection. Two general phenotypes are observed among these resistant 
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individuals: Long-term nonprogressors (LTNP) and HIV controllers (HIC). 
Approximately 5% of infected individuals are classified as LTNP, and are defined by the 
ability to maintain high CD4+ T-cell counts in the absence of HAART for 10 years or 
more. Levels of viral RNA in the blood and viral DNA in PBMCs is quite variable 
between individuals, and the majority of LTNP eventually experience a decline in their 
CD4+ T cell counts. In comparison, less than 1% of infected individuals are classified as 
HIC, as defined by having extremely low viral DNA in PBMCs, undetectable levels of 
viral RNA in the blood, and rarely showing signs of disease progression. Conversely, 
approximately 5% of individuals also experience accelerated infection kinetics, 
progressing to AIDS within 1-3 years of infection (Reviewed in [150-152]). 
Interestingly, the phenomenon of viral control during HIV infection appears to be 
spontaneous and multifactorial, with variable causes. Although the exact determinants 
responsible for rate of progression are largely unknown, several elements have been 
identified as contributing factors to prolonged control during HIV-1 infection, including 
strong CD4+ and CD8+ T cell responses [153]. Nevertheless, adaptive immune responses 
require time to develop, thus it is also believed that a number of innate immune 
mechanisms are important in limiting replication during early infection, allowing for the 
later development of strong T-cell responses [154, 155]. 
The role of innate cellular restriction factors in viral control is both controversial 
and insufficiently studied. Thus far, the primary focus has been on potential effects of 
APOBEC3 (A3) proteins, for which there are reports both supporting [156-158] and 
refuting [159, 160] potential involvement in control of HIV-1 infection. However, A3 
activity may also be misrepresented due to some reports not accounting for potential A3 
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deaminase-independent mechanisms [79], and the fact that some A3 proteins can be 
counteracted by the HIV-1 Vif protein [161]. Interestingly, loss of functional A3B was 
found to be associated with an increased risk of HIV-1 acquisition, higher viral setpoints, 
and accelerated disease progression [162]. Other reports have argued against the 
involvement of cellular restriction factors based on the observation that CD4+ T cells 
from HIC are susceptible to HIV-1 infection in vitro [163]. Alternatively, other reports 
have noted that HIC CD4+ T cells exhibit decreased susceptibility to HIV-1 infection, 
which was associated with decreased viral reverse transcription, integration, and mRNA 
transcription [164, 165]. Furthermore, the involvement of cellular factors was suggested, 
as knockdown of p21, a factor previously implicated in control of HIV-1 replication [166, 
167], resulted in increased viral reverse transcripts and mRNA production in CD4+ T 
cells from HIC. It was also noted that resistance to infection could be overcome with high 
viral inocula [164, 165]. Regardless, this narrow focus and lack of research has resulted 
in the under-appreciation of HIV-1 restriction factors as potential contributors to control 
of HIV-1 infection. 
A number of genetic factors are also believed to have a role in some cases of HIV 
control. It has been observed that individuals homozygous for the aforementioned 
CCR5/Δ32 mutation are resistant to HIV-1 infection [4-6], and a heterozygous genotype 
is associated with a number of LTNP [6, 168, 169]. Alternatively, it has been observed 
that mutations in the CCR5 promoter resulting in increased CCR5 expression are 
associated with rapid progression to AIDS [170]. In addition, certain human leukocyte 
antigen (HLA) haplotypes appear to be associated with disease progression, such as 
HLA-B57 and HLA-B27, which are consistently overrepresented in HICs [163, 171-
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174]. Interestingly, single-nucleotide polymorphisms (SNPs) have been identified as a 
contributing factor to variation in viral load set-points during asymptomatic early 
infection [175] – a stage that holds important implications for rate of disease progression 
[176]. 
A SNP is defined as a single nucleotide variation in a given genomic DNA 
sequence between an individual and other members of that species. Biological 
consequences of SNPs can vary from benign synonymous mutations, and missense 
mutations resulting in single amino acid substitutions, to more severe nonsense and 
frameshift mutations. These mutations result in the production of a premature stop 
codons and vastly altered amino acid sequences, respectively, which in turn can 
potentially lead to inactivation of the normal biological activity of the affected protein. 
Interestingly, it has been observed that SNPs in the TRIM5α gene may have an impact on 
both the susceptibility to HIV-1 infection, as well as the clinical course of HIV-1 
infection [177, 178]. Similarly, certain SNPs in the APOBEC3H gene have been shown to 
have effects on the stability and subcellular localization of A3H, which subsequently 
corresponded to variable degrees of HIV-1 restriction. Furthermore, A3H variants were 
also resistant to Vif, the HIV-1 protein responsible for the degradation of A3F/G [179-
181]. In addition, an association of certain A3H haplotypes with natural resistance to 
HIV-1 infection was observed, highlighting the fact that SNPs and restriction may have 
implications on disease progression to AIDS [182]. 
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1.7 Hypothesis and specific aims 
Preliminary data obtained in the Barr laboratory has identified a long and short 
isoform of TRIM22, resulting from one of many SNPs in the trim22 gene. These 
naturally occurring differences in the trim22 gene can be exploited to further investigate 
the biological role(s) of TRIM22, and to help elucidate specific domains and amino acids 
that are important for its functions. The overall objective of my thesis project was to 
characterize a long and short isoform of TRIM22 and compare their ability to inhibit 
HIV-1 replication. I hypothesized that these long and short isoforms of TRIM22 differ in 
their ability to restrict HIV-1 replication, and that this difference is attributed to different 
mechanisms of restriction. 
To address this hypothesis, my specific aims are: 
(i) To identify and associate currently published TRIM22 isoforms to known 
TRIM22 functions. 
(ii) To determine the pattern of localization of the long and short TRIM22 isoforms. 
(iii) To compare the restrictive capabilities of the long and short TRIM22 isoforms. 
(iv) To compare the ability of the long and short TRIM22 isoforms to restrict viral 
transcription. 
(v) To identify the allele present at a known trim22 SNP in commonly used cell lines. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Cells and cell lines 
 Cells were maintained in standard growth medium (Dulbecco‟s Modified Eagle‟s 
Medium for adherent cells and RPMI-1640 for suspension cells), supplemented with 10% 
heat-inactivated Fetal Bovine Serum, 100 U/mL Penicillin and 100 μg/mL Streptomycin 
at 37°C with 5% CO2. Cell lines were obtained from American Type Culture Collection 
unless otherwise stated. HOS-CD4/CXCR4 was provided by Dr. F. Bushman (University 
of Pennsylvania, USA). The following reagent was obtained through the NIH AIDS 
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: (GHOST (3) 
R3/X4/R5; Cat. 3943) from Dr. Vineet N. KewalRamani and Dr. Dan R. Littman [183]. 
PBMCs were isolated from whole blood from healthy volunteers using a Ficoll Hypaque 
(Sigma) gradient according to the manufacturer‟s instructions. Informed consent was 
obtained from all subjects according to the ethics protocol #16682E, approved by The 
University of Western Ontario Research Ethics Board for Health Sciences Research 
Involving Human Subjects (HSREB) (Appendix 3). 
2.2 Plasmids, transfections, and antibodies 
The plasmid encoding TRIM22α (pTRIM22α) was previously described by Barr, 
et al. [134], and the TRIM22β plasmid (pTRIM22β) was purchased from Open 
Biosystems. Both plasmids were previously modified by our lab to express N-terminal 
HA-FLAG tags. The plasmid encoding TRIM22β containing a deleted B30.2 domain 
(TRIM22β-ΔB30.2) was previously generated in our lab, and is also N-terminally FLAG-
tagged. The promoterless empty vector plasmid pGL3 was purchased from Promega. The 
plasmid encoding codon-optimized Gag (pGag) was obtained through the NIH AIDS 
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Research and Reference Reagent Program, Division of AIDS, NIAID, NIH from Drs. 
Yingying Li, Feng Gao and Beatrice H. Hahn (p96ZM651gag-opt) [184]. The plasmid 
encoding the replication-competent provirus HIV-1 R9 was obtained from Dr. F. 
Bushman (University of Pennsylvania, USA). All plasmid transfections were performed 
using Lipofectamine 2000 (Invitrogen), except for the Gag release western blot, which 
was performed using FuGene HD. Co-transfections were performed at a 5:1 ratio (pGL3, 
pTRIM22α, or TRIM22β: pR9 or pGag-opt respectively). Antibodies: anti-TRIM22 was 
obtained from Abnova, anti-FLAG from Sigma, and anti-β-actin from Rockland. The 
following reagents were obtained through the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 p24 Monoclonal Antibody 
(183-H12-5C) from Dr. Bruce Chesebro and Kathy Wehrly [185-187]. 
2.3 Quantification of infectious virus 
Clarified supernatants containing virus particles were pelleted over a 20% sucrose 
cushion for 2 hours at 21,000 × g. Pellets were resuspended in 300 µL fresh medium with 
polybrene (20µg/mL), and used to infect GHOST(3) indicator cells at approximately 50% 
confluency in a 12-well plate. Infection was allowed to proceed for 2-3 hours, after which 
the virus media was removed and replaced with 1 mL of fresh media. Approximately 36-
48 hours later media was removed, and cells were harvested in 800 µL of 1x phosphate 
buffered saline (PBS)/10 mM EDTA. Samples were added to 5 mL round bottom tubes 
containing 200 µL of 10% formaldehyde in PBS (final concentration of 2% 
formaldehyde), and allowed to fix for at least 10 minutes before samples were analyzed 
for GFP expression by flow cytometry. 
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2.4 Western blotting 
Clarified supernatants containing Gag-only particles were pelleted over a 20% 
sucrose cushion for 2 hours at 21,000 × g. Cells were detached, centrifuged at 350 × g for 
5 minutes, and washed twice with PBS. Supernatant or cell pellets were lysed with 1× 
RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1× Complete 
Protease Inhibitor (Roche), 1% Triton X-100, 0.1% SDS). For quantitative Western 
blotting, samples were mixed with 4× loading buffer (40% Glycerol, 240 mM Tris/HCl 
pH 6.8, 8% SDS, 0.04% bromophenol blue, and 5% beta-mercaptoethanol) to a final 1× 
concentration and separated on a 10% SDS-PAGE gel. Protein was transferred to 
FluorTransW (Pall) membrane by semi-dry transfer. Western blotting was carried out by 
blocking the membrane for 1 hour in Li-cor Blocking Buffer (Li-cor Biosciences) 
followed by an overnight incubation with 1:1000 dilution of primary antibody at 4°C. 
Detection was carried out using IR dye-labelled secondary antibody (1:20,000 for 30 
minutes at room temperature) and the Li-cor Odyssey Detection System (Li-cor 
Biosciences). Densitometric analysis was performed using ImageJ 1.43 u 64-bit version 
software (NIH, USA). 
2.5 Reverse transcription polymerase chain reaction 
Total RNA was isolated from transfected cell lysates using the PureLink RNA 
Mini Kit (Invitrogen) and reverse transcribed using M-MLV reverse transcriptase and 
poly dT primers according to manufacturer‟s instructions (Invitrogen). Quantitative real-
time PCR was performed using Brilliant II SYBR Green QPCR Master Mix (Agilent 
Technologies) and primer pairs specific for HIV-1 Gag (fwd: 5‟ AAT GAT GAC AGC 
ATG TCA GGG 3‟; rev: 5‟ TAC AGT TCC TTG TCT ATC GGC 3‟), or β-actin (fwd: 5‟ 
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GGT CAT CAC CAT TGG CAA TGA GCG G 3‟; rev: 5‟ GGA CTC GTC ATA CTC 
CTG CTT GCT G 3‟). Results were expressed as the relative fold-difference between 
control cells and cells expressing TRIM22. 
2.6 SNaPshot PCR 
Total genomic DNA was isolated from cell lysates using the PureLink Genomic 
DNA Mini Kit (Invitrogen), and a 597 base pair region of the trim22 B30.2 domain was 
amplified by PCR using the following primers: TRIM22 forward- 5‟ GGA TCA GAG 
ACA AGT GAA AAC TTT TGG TGT CTT CGG CTG CC 3‟; TRIM22 reverse- 5‟ 
ACG TTC TAG ATC AGG AGC TCG GTG GGC ACA CAG 3‟. Samples were sent for 
SNaPshot PCR analysis using the primer: TRIM22 SNP primer 5'- AGG AAA ACC 
CCA ATA CGA CAG GG -3'. This unique primer binds directly upstream of the SNP of 
interest, and a PCR extension is performed using fluorescence labelled 
dideoxynucleotides (ddNTP), with each of the four nucleotides (A, T, C, G) conjugated 
to a different wavelength molecule. The use of ddNTPs ensures only one base is added 
during the extension, providing a specific fluorescent signal corresponding to the 
incorporated nucleotide, representing the allele present at the SNP of interest. 
2.7 Confocal Immunofluorescence Microscopy 
Adherent cells were cultured overnight in 12-well plates on 18 mm coverslips to 
approximately 80% confluency. For suspension cells, approximately 1 x 10
6
 cells/well 
were seeded into 12-well plates immediately prior to interferon treatment. For interferon 
stimulation, media was replaced with fresh media containing recombinant human 
interferon β-1b (Pestka Biomedical Laboratories) at a final concentration of 500 U/mL. 
For suspension cells, following a 24 hour treatment with IFN-β, cells were centrifuged at 
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350 × g for 5 minutes, resuspended in 300 µL of 1x PBS, and allowed to settle on poly-L-
lysine coated coverslips for at least 1 hour at 37°C. For transfections, cells were 
transfected with pTRIM22α, pTRIM22β, or pTRIM22β-ΔB30.2 using Lipofectamine 
2000 according to manufacturer‟s instructions (Invitrogen). Twenty-four hours post-
transfection/stimulation, the coverslips containing the cells were washed twice with PF 
buffer (1× PBS + 1% FBS), and fixed for 10 minutes in 1× PBS containing 5% 
formaldehyde and 2% sucrose, permeabilized in 1× PBS containing 5% NP-40 and then 
washed twice more with PF buffer. The coverslips were incubated with primary 
antibodies for one hour, washed 6× with PF buffer, incubated with secondary antibodies 
(Alexa Fluor 546 anti-mouse or AlexaFluor 488 anti-mouse, Invitrogen) for one hour and 
then washed 6× with PF buffer. Coverslips were mounted onto glass slides with ~10 μL 
of Vectashield mounting media with DAPI (Vector Laboratories) and then sealed with 
nail polish. Slides were examined using a Zeiss LSM 510 confocal fluorescence 
microscope and images were obtained with sequential imaging. 
2.8 Molecular Modelling 
Three-dimensional models of the B30.2 domain from each TRIM22 isoform were 
built based on homologues of known structures using the web-based server 3D-JIGSAW, 
version 2.0 (http://bmm.cancerresearchuk.org/~3djigsaw/) [188, 189] using the following 
query sequences: TRIM22α 
(YWVDVMLNPGSATSNVAISVDQRQVKTVRTCTFKNSNPCDFSAFGVFGCQYFS
SGKYYWEVDVSGKIAWILGVHSKISSLNKRKSSGFAFDPSVNYSKVYSRYRPQY
GYWVIGLQNTCEYNAFEDSSSSDPKVLTLFMAVPPCRIGVFLDYEAGIVSFFNVT
NHGALIYKFSGCRFSRPAYPYFNPWNCLVPMTVCPPSS); and TRIM22β 
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(YWVDVMLNPGSATSNVAISVDQRQVKTVRTCTFKNSNPCDFSAFGVFGCQYFS
SGKYYWEVDVSGKIAWILGVHSKISSLNKRKSSGFAFDPSVNYSKVYSRYRPQY
GYWVIGLQNTCEYNAFEDSSSSDPKVLTLFMAVPPCRIGVFLDYEAGIVSFFNVT
NHGALIYKFSGCRFSRPAYPYFNPWNCLVPMTVCPPSS). Models were visualized 
using the program Visual Molecular Dynamics (VMD), version 1.9, developed by the 
Theoretical and Computational Biophysics Group at the Beckman Institute for Advanced 
Science and Technology of the University of Illinois at Urbana-Champaign [190], using 
the MultiSeq extension. 
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CHAPTER 3: RESULTS 
3.1 Summary of the general biological characteristics of the current published 
TRIM22 isoforms 
There are currently 36 known SNPs in the trim22 gene, including multiple 
frameshift or nonsense mutations that result in the production of different truncated 
isoforms of TRIM22 (Table 1). There are currently 19 publications characterizing the 
biological function of TRIM22; however, not a single report has suitably discussed the 
potential impact that SNPs may have on these findings. Furthermore, the TRIM22 field 
appears to relate all biological functions identified to a single TRIM22 isoform. In an 
attempt to associate known TRIM22 functions with specific trim22 SNPs, I mined the 
literature to identify which TRIM22 isoforms have previously been reported. At least 4 
different isoforms of TRIM22 have been studied (Figure 4), and at least 5 additional 
trim22 clones have been developed without recorded nucleotide sequences (Table 2). 
Retrospective analysis has revealed that the first identified trim22 clone 
(accession number X82200) [121] was derived from an mRNA splice variant with a 4 
amino acid deletion in the coiled-coil domain. In addition, this gene, cloned from the 
Daudi cell line, appears to contain a single nucleotide deletion resulting in the production 
of a premature stop codon, and subsequently a 52 amino acid truncation of the C-
terminus. This 442 amino acid protein was suggested to restrict transcription from the 
HIV-1 LTR, however no further investigation was performed [121]. Although no 
accession numbers are given, it appears that this clone has been used in 4 additional 
studies (Table 2), including a 2006 study that demonstrated TRIM22 can restrict HIV-1 
replication in monocyte-derived macrophages [172]. 
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Table 1: Summary of known single nucleotide polymorphisms (SNPs) in the trim22 
gene. 
Nucleotide 
Position 
Codon 
Position 
Amino Acid 
Position 
Type of Mutation 
SNP 
Allele 
Resulting 
Amino Acid 
140 2 47 Missense A Glu [E] 
   Contig reference T Val [V] 
182 2 61 Missense A Asn [N] 
   Contig reference C Thr [T] 
206 2 69 Missense A Gln [Q] 
   Contig reference G Arg [R] 
268 1 90 Missense A Lys [K] 
   Contig reference G Glu [E] 
300 3 100 Synonymous C His [H] 
   Contig reference T His [H] 
313 1 105 Missense A Lys [K] 
   Contig reference C Gln [Q] 
318 3 106 Synonymous T Ile [I] 
   Contig reference C Ile [I] 
372 3 124 Synonymous G Glu [E] 
   Contig reference A Glu [E] 
463 1 155 Missense A Asn [N] 
   Contig reference G Asp [D] 
510 3 170 Synonymous T Thr [T] 
   Contig reference C Thr [T] 
537 3 179 Frameshift (Insertion) G Glu [E] 
   Contig reference  Glu [E] 
624 3 208 Synonymous C Gly [G] 
   Contig reference T Gly [G] 
642 3 214 Synonymous C Asp [D] 
   Contig reference T Asp [D] 
694 1 232 Missense G Ala [A] 
   Contig reference A Thr [T] 
725 2 242 Missense C Thr [T] 
   Contig reference G Arg [R] 
731 2 244 Missense T Leu [L] 
   Contig reference C Ser [S] 
763 1 255 Missense A Ile [I] 
   Contig reference G Val [V] 
790 1 264 Missense A Met [M] 
   Synonymous C Leu [L] 
   Contig reference T Leu [L] 
836 2 279 Missense A Gln [Q] 
   Contig reference G Arg [R] 
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Nucleotide 
Position 
Codon 
Position 
Amino Acid 
Position 
Type of Mutation 
SNP 
Allele 
Resulting 
Amino Acid 
881 2 294 Missense A Lys [K] 
   Contig reference C Thr [T] 
913 1 305 Synonymous T Leu [L] 
   Contig reference C Leu [L] 
936 3 312 Synonymous A Ser [S] 
   Contig reference G Ser [S] 
962 2 321 Missense A Lys [K] 
   Contig reference G Arg [R] 
980 2 327 Missense A His [H] 
   Missense T Leu [L] 
   Contig reference G Arg [R] 
1035 3 345 Synonymous T Phe [F] 
   Contig reference C Phe [F] 
1056 3 352 Synonymous A Ser [S] 
   Contig reference G Ser [S] 
1092 3 364 Missense T Asn [N] 
   Contig reference G Lys [K] 
1134 3 378 Synonymous T Leu [L] 
   Contig reference G Leu [L] 
1203 3 401 Synonymous C Tyr [Y] 
   Contig reference T Tyr [Y] 
1244 2 415 Missense T Ile [I] 
   Contig reference C Thr [T] 
1316 2 439 Frameshift (Deletion)  Leu [L] 
   Contig reference C Pro [P] 
1320 3 440 Frameshift (Insertion) C Pro [P] 
   Contig reference  Pro [P] 
1324 1 442 Missense T Cys [C] 
   Contig reference C Arg [R] 
1364 2 455 Nonsense A Stop [X] 
   Contig reference C Ser [S] 
1414 1 472 Missense A Ser [S] 
   Contig reference T Cys [C] 
1473 3 491 Missense A Ile [I] 
   Contig reference G Met [M] 
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Table 2: Summary of trim22 clones used in literature. 
Accession 
Number 
First 
Published 
Length 
(bp; aa) 
Reported Source Notes/Unique Features
 a
 Reported Use
 b
 
(By reference) 
X82200 1995 
1329; 
442 
cDNA from Daudi cell line 
a) Splice variant: 
- Missing NT 519-531 (AA 174-177) 
b) SNP at NT 725 (AA 242); R-->T 
c) SNP at NT 1316; Deletion 
- Premature stop codon at NT 1326 
- Unique C-term ("LPVVLGFS") 
[105, 121, 125, 131, 
135] 
BC035582
 c
 2002 
1497; 
498 
cDNA from testis 
Available through Open Biosystems: 
TRIM22-pCMV-SPORT6 (ID: 5583800) 
[144, 146, 191-194] 
N/A 2006 N/A cDNA from human placenta Sequence unknown. [195, 196] 
NM_006074 2007 
1497; 
498 
Open Biosystems SNP at NT 642; Synonymous [197] 
N/A 2008 N/A CDS from human PBMCs Sequence unknown. [130, 132, 198] 
N/A 
d
 2008 
1347; 
448 
Coding region subcloned from 
X82200
 e
 
a) Splice variant: 
- Missing NT 519-531; AA 174-177 
b) SNP at NT 725; R-->T (AA 242) 
c) Primers based off X82200: 
- No SNP at NT 1316, therefore 
  no stop codon at NT 1326 
- NT 1330-1347 from pcDNA3.1 backbone 
- Unique C-term ("ARACI") 
[134] 
N/A 2009 N/A cDNA sequence Sequence unknown. [199] 
HQ_842635 2011 
1497; 
498 
Gene from U937 nonpermissive 
cells 
a) SNP at NT 463; D-->N (AA 155) 
b) SNP at NT 725; R-->T (AA 242) 
[144] 
N/A 2011 N/A 
CDS from monocyte-derived 
dendritic cells/macrophages 
f
 
Sequence unknown. [144] 
 
a Variations listed in relation to the BC035582 reference sequence. 
b Due to no accession number listed, use is only suspected in some references listed, based on publication year and source listed as N. Mechti. 
c Denoted as TRIM22β throughout this thesis. 
d Denoted as TRIM22α throughout this thesis. 
e Reported source may not be accurate, due to lack of SNP at nucleotide 1316. 
f Cells were stimulated with IFNβ and lipopolysaccharide. 
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In 2008, Barr, et al. observed that a similarly truncated, 448 amino acid TRIM22 
protein (from here referred to as TRIM22α) (Figure 4) (Table 2) was also capable of 
restricting HIV-1 replication. In contrast to the effects on transcription observed by Tissot 
and Mechti (1995), TRIM22α was shown to interfere with Gag trafficking to the plasma 
membrane of HOS cells [134]. Furthermore, TRIM22α was observed to restrict HIV-1 
replication in multiple cell lines. Of note, intracellular Gag levels in the HOS and HeLa 
cell lines appeared unaffected by TRIM22α expression, yet were dramatically reduced in 
the U2OS and 143b cell lines, suggesting that certain TRIM22 functions may be cell-type 
specific [134]. 
A full-length (498 amino acid) protein was more recently reported to also block 
HIV-1 replication and LTR-mediated transcription [144]. However, a deeper look into 
the TRIM22 clones used revealed that this study used three different clones throughout 
the study, at least two of which contain unique SNPs (Table 2). One clone, which had 
been described in earlier studies, is a 498 amino acid protein, with a nucleotide sequence 
matching the trim22 consensus sequence (BC035582, from here referred to as 
TRIM22β). In addition, a novel clone was created from the trim22 gene in non-
permissive U937 cells, for which the sequence is published (HQ_842635). Although the 
new clone is also 498 amino acid in length, it contains SNPs at nucleotides 463 and 725, 
which result in amino acid substitutions at positions 155 and 242, respective to 
TRIM22β. A third trim22 coding sequence was also cloned from a mix of stimulated 
monocyte-derived macrophages and dendritic cells, for which no sequence is provided. 
Furthermore, it is somewhat unclear which trim22 clones are used for which experiments, 
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resulting in additional uncertainty surrounding the potential effects of SNPs on TRIM22 
function. 
It appears that at least three other trim22 clones have been independently 
produced and used for various studies (Table 2). No sequences have been published for 
these clones, nor have any accession numbers been given. In addition, several other 
groups have studied TRIM22 during in vivo studies without any indication of which 
isoform was studied. As a result, it is unclear which TRIM22 isoforms are associated 
with which biological functions of TRIM22. Taken together, these findings show that a 
number of different TRIM22 isoforms have been used in the literature, and multiple 
isoforms have been shown to restrict HIV-1 replication. 
3.2 The TRIM22α and TRMI22β isoforms exhibit different patterns of 
localization 
According to published reports, the subcellular localization of TRIM22 appears to 
be variable and dynamic. Some reports show TRIM22 to be cytoplasmic [105, 199], 
whereas others show it to be nuclear [130, 132, 193, 198] or both [144, 191, 192, 197] 
(Table 3). Furthermore, TRIM22 has been shown to localize to Cajal bodies [191], the 
centrosome, or vimentin containing aggresome-like structures next to the endoplasmic 
reticulum [192]. These reports do not discuss the discrepancies observed between the 
various TRIM22 localization patterns. Possible explanations for these observed 
discrepancies in subcellular localization include cell type differences, endogenous versus 
exogenous expression of TRIM22, different TRIM22 isoforms (long versus short), and 
genetic variability in the TRIM22 isoforms studied (SNPs). 
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Table 3: Summary of the localization patterns observed for TRIM22 in literature. 
Localization Pattern Cell Type Epitope Tag Reference 
Cytoplasm Diffuse 293T GFP or V5/His [199] 
 Diffuse COS7 GFP or V5/His [199] 
 Diffuse HeLa Endogenous [199] 
 Diffuse with speckles/bodies HeLa GFP [105] 
 Diffuse HeLa GFP or V5/His [199] 
 Diffuse PBMCs Endogenous [199] 
 Diffuse with speckles/bodies U2OS GFP [105] 
Cytoplasm & 
Nucleus 
Nucleoplasmic, with nuclear 
bodies
1
 
ABC28 Endogenous [191] 
 Nuclear and cytoplasmic bodies 293T HA [144] 7 
 
Diffuse throughout, or nuclear 
bodies
2
 
HeLa EGFP [191] 7 
 
Nucleoplasmic, with nuclear 
bodies 
HeLa Endogenous [191] 
 Diffuse, with cytoplasmic bodies
3
 HeLa FLAG [197] 
 Nucleoplasmic with NB
4
 MCF7 
EGFP, EYFP, or 
FLAG 
[191] 7 
 
Nucleoplasmic, with nuclear 
bodies 
MCF7 Endogenous [191] 
 Nucleoplasmic and cytoplasmic T47D Endogenous [191] 
 Diffuse with speckles
5,6
 U2OS Endogenous [192] 
Nucleus Aggregates/bodies 293T Myc [130] 
 Aggregates/bodies COS7 Myc [198] 
 Diffuse with speckles/bodies HepG2 Endogenous [132] 
 Diffuse with speckles/bodies HepG2 Myc [132] 
 Diffuse with bodies MCF7 FLAG [193] 7 
1 Some co-localization with fibrillarin (Nucleoli). 
2 Pattern changes with cell cycle phase; 
  (G0/G1 = Nuclear Bodies; S-Phase = Nuclear speckles & cytoplasmic; Mitosis = Diffuse throughout cell). 
3 TRIM22 plasmid was co-expressed with Rhesus TRIM5α. 
4 Partial co-localization with Cajal bodies. 
5 Potential co-localization with calnexin (Endoplasmic reticulum). 
6 Partial co-localization with the centrosome. 
7 Same clone as TRIM22β isoform.
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To determine if the localization of endogenous TRIM22 varied between cell 
types, several cell lines were treated with IFNβ to induce TRIM22 expression and 
analyzed by confocal immunofluorescence microscopy (Figure 5). Cells were harvested 
24 h later, and expression was detected using a TRIM22 monoclonal antibody. 
Interestingly, TRIM22 exhibited a variety of localization patterns, depending on the cell 
type observed. In the U2OS, HOS, 293T, and HeLa cell lines, TRIM22 localized 
primarily in the nucleus in a diffuse to punctate pattern, however some TRIM22 also 
localized in the cytoplasm (Figure 5a). In the T cell lines Jurkat E6.1 and H9, TRIM22 
localized in a diffuse to punctuate pattern throughout the cytoplasm (Figure 5b). PBMCs 
from two different donors were isolated and treated with IFNβ to induce TRIM22 
expression. Interestingly, TRIM22 localized exclusively in clusters in the nucleus of cells 
from one donor, whereas in the second donor, TRIM22 localized predominantly in the 
cytoplasm (Figure 5c). 
To eliminate potential cell-type differences, which may in turn impact TRIM22 
function and localization, a single cell line was chosen to study the TRIM22α and 
TRIM22β isoforms. U2OS cells were chosen based on previous observations by Barr, et 
al. demonstrating that TRIM22α expression not only restricted release of HIV-1 from 
U2OS cells, but also resulted in decreased levels of intracellular Gag. Conversely, 
TRIM22α expression in HOS cells was only capable of restricting release of HIV-1, and 
had no effect on intracellular Gag levels. This is particularly interesting because it was 
observed that TRIM22α expression resulted in altered Gag trafficking in HOS cells, but 
no mechanism was ever investigated in U2OS cells [134]. As TRIM22β expression has 
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Figure 5: Subcellular localization of endogenous TRIM22 in multiple cell lines. 
All cells were treated with 500 U/ml of recombinant IFN-β overnight to induce TRIM22 
expression. Cells were fixed and stained with mouse anti-human TRIM22 antibody, and 
with secondary anti-mouse AlexaFluor 488 or AlexaFluor 546. A) TRIM22 primarily 
localized to the nucleus of several non-lymphoid cell lines (U2OS, 293T, HeLa, HOS). 
B) TRIM22 primarily localized to the cytoplasm of the T-cell lines (Jurkat E6.1, H9). C) 
TRIM22 exhibited different patterns of localization in PBMCs from two different donors. 
In donor 1, TRIM22 primarily localized to the cytoplasm in a diffuse/punctate pattern, 
whereas in donor 2, TRIM22 primarily localized to the nucleus and appeared to organize 
into nuclear bodies. 
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been shown to block transcription from the HIV-1 LTR [144], we sought to determine 
which mechanism of action was active in U2OS cells. 
To determine the localization of TRIM22α and TRIM22β, plasmids encoding 
each isoform with an N-terminal FLAG-tag were individually transfected into U2OS 
cells. Cells were harvested 24 hours after transfection, stained with FLAG antibodies, and 
analyzed using confocal immunofluorescence microscopy (Figure 6). We observed that 
TRIM22α localized predominantly in the cytoplasm, and exhibited a diffuse pattern of 
localization. Conversely, TRIM22β localized predominantly in the nucleus and often 
appeared to localize in clusters. Taken together, these findings reveal that TRIM22 
exhibits a range of localization patterns, which is likely influenced by several factors. It 
appears that differences in cell lines, cell types, TRIM22 isoforms, genetics, and 
endogenous vs. exogenous expression may play a role in determining the localization of 
TRIM22. 
3.3 The B30.2/SPRY domain of TRIM22β is important for nuclear localization 
Given that the nuclear TRIM22β isoform has a B30.2 domain that is 50 amino 
acids longer than the cytoplasmic TRIM22α isoform, we hypothesized that this domain 
helps dictate the subcellular localization of TRIM22. To determine if the B30.2/SPRY 
domain is required for nuclear localization, a plasmid encoding a FLAG-tagged 
TRIM22β isoform with the B30.2/SPRY domain deleted (TRIM22β-ΔSPRY, previously 
made in our laboratory) was transfected into U2OS cells and analyzed using confocal 
immunofluorescence microscopy (Figure 6). We observed that deletion of the 
B30.2/SPRY domain abolished the nuclear localization of TRIM22β, resulting in a 
diffuse cytoplasmic pattern that closely resembled the localization pattern of TRIM22α. 
44 
 
 
 
 
Figure 6: Subcellular localization of different TRIM22 isoforms in U2OS cells. 
U2OS cells were transfected with plasmids encoding one of the TRIM22 isoforms. 
Twenty-four hours post-transfection, cells were fixed and stained with mouse anti-FLAG 
antibody, and with secondary anti-mouse AlexaFluor 488. TRIM22α exhibited diffuse 
localization throughout the cytoplasm, whereas TRIM22β predominantly localized to the 
nucleus in a nuclear body pattern. Deletion of the B30.2 domain of TRIM22β abolished 
body formation and nuclear localization. 
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In addition, multiple reports have noted similar findings [132, 193, 199], supporting the 
conclusion that the B30.2/SPRY domain is required for the nuclear localization of 
TRIM22β. 
It has been previously reported that the Spacer 2 domain of TRIM22 contains a 
predicted bi-partite nuclear localization signal (NLS) at amino acids 265 to 269 [121] 
(Figure 4). Conversely, there are no predicted NLS consensus sequences in the B30.2 
domain; however, a KRK sequence is present at amino acid 380 (Figure 4). While this 
does not match the Lys-Arg/Lys-X-Arg/Lys consensus NLS sequence described by 
Chelsky, et al. [200], other groups have shown that the KRK sequence is sufficient to 
direct nuclear localization of several proteins, such as SHP-1 [201, 202]. As a result, we 
hypothesized that the presence of amino acid substitutions and/or deletions in the B30.2 
domain may alter its structure and hide this KRK sequence, resulting in altered 
localization patterns. 
Although the crystal structure of TRIM22 is yet to be solved, molecular modeling 
of the B30.2 domain from TRIM22α/β was performed using the programs 3D-JIGSAW 
and Visual Molecular Dynamics (Figure 7). The TRIM22α and TRIM22β B30.2 domain 
models were assigned accuracy scores of 5.40 and 5.69, respectively, indicating over 
95% probability that the query and template sequences alignments are accurate. Although 
the position of the KRK sequence is not directly affected by the truncation, we did note 
the appearance of a large pocket in the TRIM22α B30.2 domain that is partially filled by 
the additional amino acids present in TRIM22β (Figure 7a). In addition, the TRIM22β 
B30.2 domain contains four anti-parallel β-sheets, two of which are lost in the TRIM22α
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Figure 7: Molecular modelling of the B30.2 domain from different TRIM22 
isoforms. 
Molecular modelling was used to predict the structure of the B30.2 domain from different 
TRIM22 isoforms. The B30.2 domain from TRIM22α is depicted in orange, and that 
from TRIM22β is depicted in blue. The KRK NLS sequence is highlighted in red. The 
overlay frames illustrate the TRIM22α B30.2 domain with the C-terminal 50 amino acids 
from TRIM22β overlaid in green to accentuate the differences between the two isoforms. 
A) A large pocket is visible in the TRIM22α B30.2 domain that is partially filled by the 
additional amino acids possessed by TRIM22β, as indicated by the white arrow. B) A 
plane of four anti-parallel β-sheets present in the TRIM22β B30.2 domain is disrupted in 
the TRIM22α structure, as indicated by the white arrow. 
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structure (Figure 7b). While it is clear that B30.2 domain is important, the role that these 
features play in controlling localization requires further investigation. 
3.4  The TRIM22α and TRIM22β isoforms possess different degrees of HIV-1 
restriction in the same cell type 
Although different short and long TRIM22 isoforms have independently been 
shown to restrict HIV-1 replication in vitro [131, 134, 144, 145], the degree to which 
these isoforms restrict HIV-1 in comparison to each other is unknown. To determine and 
compare the restriction capabilities of TRIM22α and TRIM22β in vitro, we performed 
HIV-1 release assays. In brief, plasmids encoding a TRIM22 isoform (or empty vector 
control) and a replication-competent HIV-1 provirus (pR9) were co-transfected into 
either HOS-CD4/CXCR4 or U2OS cells. After 48 hours, supernatants containing virus 
were collected, clarified via low-speed centrifugation, and used to infect the HIV reporter 
cell line GHOST (3) X4/R5. This reporter cell line supports HIV-1 replication and 
contains a green fluorescent protein (GFP) construct under the transcriptional control of 
the HIV-2 LTR promoter, thus cells that become infected will express GFP. Infections 
were allowed to proceed for 48 hours, after which the level of infection was quantified by 
determining the percentage of GFP-expressing cells using flow cytometry. 
As shown in Figure 8, both TRIM22 isoforms substantially inhibited the release of 
infectious HIV-1 particles from HOS-CD4/CXCR4 cells and U2OS cells. HOS-
CD4/CXCR4 cells expressing the TRIM22α isoform exhibited a 1.3-fold reduction in 
virus release, whereas the TRIM22β isoform resulted in a 2.8-fold reduction in virus 
release, compared to cells transfected with a vector control. Notably, the effects of both 
isoforms appeared to be much more potent in U2OS cells. Expression of TRIM22α and
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Figure 8: The TRIM22α and TRIM22β isoforms vary in their ability to restrict 
release of infectious HIV-1 particles. 
HOS-CD4/CXCR4 and U2OS cells were co-transfected with plasmids encoding a 
replication-competent HIV-1 provirus (pR9), and TRIM22α, TRIM22β, or the control 
empty expression vector pGL3. Virus supernatants were collected 48 hours post-
transfection, and used to infect the reporter cell line GHOST(3) X4/R5. Infection was 
allowed to proceed for 48 hours, after which GHOST(3) X4/R5 cells were harvested, 
fixed, and analyzed for GFP expression by flow cytometry. Results (percentage of cells 
fluorescing) are presented as fold difference compared to the pGL3 vector control, and 
represent the amount of infectious virus released from the transfected HOS-CD4/CXCR4 
and U2OS cells. 
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TRIM22β in U2OS cells resulted in approximately a 10-fold and 20-fold reduction in 
virus release, respectively, compared to cells transfected with a vector control. Taken 
together, these data show that TRIM22α and TRIM22β both effectively inhibit release of 
infectious HIV-1 particles; however the actions mediated by TRIM22β appear to be more 
dominant. 
3.5 The TRIM22α and TRIM22β isoforms restrict transcription from viral 
promoters to varying degrees 
Previous reports have shown that TRIM22α alter trafficking of the Gag 
polyprotein to the plasma membrane [134], and TRIM22β can inhibit transcription from 
the HIV-1 LTR [144]. Interestingly, TRIM22α also prevents the accumulation of 
intracellular Gag polyprotein when co-expressed with an HIV-1 provirus in U2OS cells 
[134], suggesting it may also block LTR-mediated transcription. We therefore sought to 
compare the ability of the TRIM22α and TRIM22β isoforms to block HIV-1 LTR 
transcription during a productive infection in vitro. Plasmids encoding a TRIM22 isoform 
(or empty vector control) and a replication-competent HIV-1 provirus (pR9) were co-
transfected into U2OS cells. Cells were harvested 48 hours post-transfection and total 
mRNA was harvested and reverse transcribed using poly d(T) primers. HIV-1 LTR 
transcription was assessed via quantitative real-time PCR (qPCR) using primers specific 
to a region of the HIV-1 gag gene. The β-actin gene was amplified as a loading control, 
and CT values for gag were normalized to β-actin levels prior to analysis. We observed 
that both TRIM22α and TRIM22β inhibited transcription from the HIV-1 LTR, resulting 
in approximately a 3-fold and 20-fold reduction in gag cDNA levels, respectively, 
compared to cells transfected with a vector control (Figure 9a). 
51 
 
 
 
Figure 9: The TRIM22α and TRIM22β isoforms vary in their ability to restrict 
transcription from viral promoters. 
U2OS cells were co-transfected with plasmids encoding TRIM22α, TRIM22β, or the 
control empty expression vector pGL3, and (A) a replication-competent HIV-1 provirus 
(pR9) or (B) a plasmid encoding Gag under the control of the CMV promoter (pGag-opt). 
Total cellular mRNA was reverse transcribed and cDNA was analyzed by quantitative 
real-time PCR (qPCR) using primers specific to a region of the gag gene, and primers 
amplifying β-actin as a loading control. Results were normalized to β-actin levels, and are 
expressed as relative fold change in expression compared to the pGL3 vector control. 
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To determine if these effects on transcription were unique to the HIV-1 LTR, the 
experiment was repeated using a plasmid encoding a codon optimised Gag polyprotein 
under control of a CMV promoter (pGag-opt), instead of an HIV-1 provirus. TRIM22α 
and TRIM22β inhibited transcription from the CMV promoter in a similar manner to the 
LTR, resulting in approximately a 2-fold and 11-fold reduction in gag cDNA levels, 
respectively, compared to cells transfected with a vector control (Figure 9b). To confirm 
this effect at the protein level, the TRIM22/pGag-opt co-transfection was repeated, and 
samples were harvested 48 hours post-transfection. Clarified supernatants were 
centrifuged over a sucrose cushion to pellet Gag VLP, and a western blot was performed 
on the cell lysate and supernatant fractions (Figure 10). Densitometric quantification 
revealed that TRIM22α and TRIM22β reduced the amount of intracellular Gag by 
approximately 1.76-fold and 1.57-fold, respectively, in addition to restricting the amount 
of Gag VLP released by 1.75-fold and 1.51-fold, respectively. 
3.6 Several commonly used cell lines are negative for an SNP insertion in the 
trim22 gene 
The level of impact that SNPs have on controlling HIV-1 infection is yet to be 
determined; however, it is clear that they are an important contributing factor [175]. This 
concept is easily observed in individuals homozygous for the CCR5/Δ32 mutation, which 
confers robust resistance to HIV-1 infection [4-6]. Polymorphisms in host innate 
immunity genes that inhibit HIV-1 replication have also been shown to impact HIV-1 
infection and disease progression. For example, certain SNP profiles for the APOBEC3H 
gene have been shown to not only affect the stability and subcellular localization of A3H, 
but also its capacity to restrict HIV-1 replication [179-181] and slow disease progression 
[182]. Recent observations have shown that trim22 expression may be associated with 
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Figure 10: The TRIM22α and TRIM22β isoforms block release of HIV-1 Gag-only 
particles. 
U2OS cells were co-transfected with plasmids encoding TRIM22α, TRIM22β, or the 
control empty expression vector pGL3, and a plasmid encoding Gag under the control of 
the CMV promoter (pGag-opt). Cells and supernatants were harvested 48 hours post-
transfection, and Gag particles were pelleted by centrifugation. A western blot was 
performed on the cell and supernatant fractions using p24CA (anti-Gag) antibodies. 
Densitometric analysis was performed using ImageJ software, and is indicated by the 
numbers. 
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viral control during primary HIV-1 infection [145]. In addition, we have shown here that 
the localization patterns and potency of antiviral activity appear to vary between TRIM22 
isoforms. The TRIM22α isoform localized to the cytoplasm and exhibited less antiviral 
activity than the nuclear localized TRIM22β. These isoforms may also possess different 
antiviral mechanisms, as demonstrated by the potent transcriptional repression exhibited 
by TRIM22β (Figure 9), and the ability for TRIM22α to alter trafficking of the HIV-1 
Gag protein [134]. 
Although the TRIM22α isoform is not the direct result of an SNP, at least 3 
trim22 SNPs result in the production of isoforms very similar to TRIM22α. As similar 
sized TRIM22 isoforms likely have similar characteristics, we were interested in 
determining if any of these SNPs are present in the trim22 gene from several commonly 
used cell lines. Due to financial constraints, we were only able to investigate a single 
SNP at the time of this study. We chose to determine the allele located at NT position 
1320, as this position is subject to a known SNP insertion, resulting in a frameshift 
mutation, and subsequently the creation of a premature stop codon. The corresponding 
truncated protein is of similar length and sequence to the TRIM22α protein used in our 
studies, thus this SNP holds interesting implications for the localization and function of 
endogenous TRIM22 observed in these cell lines. Genomic DNA was first extracted from 
each cell line, the full B30.2 domain was amplified for each sample, and all samples were 
sent for SNaPshot PCR analysis. This technique is a quick and economical approach to 
rapidly identify specific SNPs of interest (see Methods for details). As seen in Table 4, all 
samples were identified to contain the consensus allele, indicating that they do not 
contain an insertion at position 1320. It will be important to investigate the presence of 
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other SNPs in these genes, as a frameshift mutation at position 1316, as well as a 
nonsense mutation at position 1364, also result in similarly sized TRIM22 isoforms. 
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Table 4: List of alleles present at nucleotide 1320 in commonly used cell lines, as 
reported by SNaPshot PCR. 
Cell Line Allele 
143b A 
293T A 
CEM-SS A 
HeLa A 
HOS A 
Jurkat A 
THP-1 A 
U2OS A 
U937 A 
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CHAPTER 4: DISCUSSION 
The data detailed in this thesis clearly show that a short and a long TRIM22 
isoform (TRIM22α and TRIM22β, respectively) possess different biological 
characteristics and antiviral capabilities. We have observed that these isoforms possess 
different patterns of localization, which molecular modelling suggests may be due to a 
change in the structure of the B30.2/SPRY domain. Although both isoforms have 
independently been reported to restrict HIV-1 replication [134, 144], this is the first direct 
comparison of two TRIM22 isoforms. Furthermore, we have shown that these isoforms 
exhibit different degrees of HIV-1 restriction, which is, at least in part, due to inhibition 
of transcription from the 5‟ LTR. Nevertheless, this transcriptional block is not specific to 
the HIV-1 LTR, as both isoforms were also capable of restricting transcription from the 
CMV promoter. 
Several complications arise when studying TRIM22 due to i) contradictory 
reports on biological function, ii) potential cell type differences, iii) the existence of 
numerous reported SNPs in the trim22 gene, and iv) the failure to identify the specific 
TRIM22 isoform used in certain published studies. To better understand the potential 
impact of trim22 SNPs, we mined the literature and summarized the information 
currently known about TRIM22 functions. We have presented a list of 36 known SNPs in 
the trim22 gene (Table 1). This list includes 4 SNPs known to result in the production of 
premature stop codons, and thus shorter TRIM22 proteins, similar to the TRIM22α 
isoform used in this study. We have also shown that no fewer than four unique TRIM22 
isoforms have been used in past literature, along with at least four additional trim22 
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clones for which no sequence information has been published (Table 2). Taken together, 
these data help to highlight the importance of studying the effects of trim22 SNPs and 
demonstrate that different TRIM22 isoforms possess varying degrees of activity. 
The importance of reporting SNPs/isoforms is abundantly clear in the case of 
APOBEC3H, as its stability, localization and ability to restrict HIV-1 replication and 
slow disease progression have all been linked to SNPs [179-182]. While we are only 
beginning to uncover the impact that SNPs may have on TRIM22 function, the recent 
observation that trim22 expression may be associated with viral control during primary 
HIV-1 infection [145] stresses the importance of proper documentation and 
understanding of trim22 SNPs in the literature. Here we used SNaPshot PCR to show that 
several commonly used cell lines are negative for a single nucleotide insertion at position 
1320, which is one of the SNPs resulting in a TRIM22 truncation. Unfortunately due to 
financial constraints, we have been unable to investigate any other SNPs in the trim22 
gene; however, an alternative project in our laboratory will be using this approach to 
investigate a number of SNPs in the trim22 gene from primary donors.  
While the biological impact of trim22 SNPs is still largely unknown, there is no 
doubt that some of the variation between TRIM22 reports is a result of different isoforms 
being studied. This point is highlighted by the fact that TRIM22α and TRIM22β have 
been previously shown to restrict HIV-1 replication by separate mechanisms [134, 144], 
and several reports have observed a range of different localization patterns for TRIM22 
(Table 3). In addition, numerous studies have investigated the functions of endogenous 
TRIM22 in different samples/cell lines with unsequenced trim22 genes. Unfortunately, 
without information about the possible SNPs or isoforms present, we are unable to fully 
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associate and compare these findings to other information known about TRIM22 in the 
literature. 
Several other factors have also been suggested to affect the localization of 
TRIM22, including cell type, method of fixation, and the epitope tag used for detection. 
To gain further insight into these factors, we began by investigating the localization 
pattern of IFNβ-induced endogenous TRIM22 in several common cell lines (Figure 5). 
Interestingly, endogenous TRIM22 was primarily localized to the nucleus in several non-
lymphoid cell lines (HOS, U2OS, HeLa, 293T), compared to the predominantly 
cytoplasmic localization in two T-cell lines (Jurkat E6.1, H9), suggesting that cell type 
differences may be a factor contributing to localization. Similar localization patterns have 
previously been described for IFN-induced TRIM22 expression in U2OS and HeLa cells 
[191, 192]; however another report found endogenous TRIM22 to only be present in the 
cytoplasm of HeLa cells [199]. Nevertheless, this report did not appear to induce 
TRIM22 expression by any means, which may account for the observed differences. In 
contrast, IFNβ-treated PBMCs isolated from two different donors exhibited contrasting 
patterns of localization (Figure 5c), suggesting that host genetics may also impact the 
biological characteristics of TRIM22. 
To further explore the potential effects of trim22 SNPs on localization pattern, 
U2OS cells were used to investigate two different TRIM22 isoforms previously described 
in the literature. We observed that our TRIM22α isoform, which contains a 50 amino acid 
truncation of the B30.2 domain, exhibited a predominantly diffuse pattern throughout the 
cytoplasm (Figure 6). Although many of the reports on TRIM22 localization have no 
sequence information available, a similar short form (X82200) was also observed to 
61 
 
 
 
localize predominantly to the cytoplasm of U2OS cells [105]. Interestingly, our full-
length isoform, TRIM22β, localized almost exclusively to the nucleus, and exhibited a 
diffuse pattern with nuclear bodies (Figure 6). 
We also observed that deletion of the B30.2 domain in TRIM22β resulted in a 
localization pattern nearly identical to that of TRIM22α (Figure 6). This result was not 
surprising, as multiple reports have also noted the importance of the B30.2 domain for 
TRIM22 localization [132, 193, 199]. Molecular modeling of the B30.2 domain predicted 
the presence of a large pocket (Figure 7a), as well as the loss of several β-sheets in the 
TRIM22α model (Figure 7b), although the KRK NLS sequence remains in the same 
position in both isoforms. It is possible that the TRIM22α truncation disrupts a binding 
groove/interface in the B30.2 domain that is required for interaction with proteins which 
dictate the localization of TRIM22. Nevertheless, as we are currently limited to modeling 
programs, it is also possible that the loss of amino acids in the TRIM22α B30.2 domain 
disrupts the stabilization of this domain, resulting in unfolding and complete loss of 
structure. Regardless, it appears that the C-terminal 50 amino acids are required for 
nuclear localization, thus it will be interesting to examine if the other 4 SNPs known to 
exist in this region also have an impact on subcellular localization and potentially 
function. Future experiments using more targeted mutations within the TRIM22β B30.2 
domain will help to elucidate the specific amino acids determinants for nuclear 
localization, and protein binding assays may be useful in discovering potential proteins 
that interact with this domain. 
Although TRIM22α and TRIM22β have both been shown to restrict HIV-1 
replication [134, 144], this was performed in separate studies and different cell lines, thus 
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it was important to directly compare the potency of their anti-HIV-1 activity in relation to 
each other. We co-transfected HOS and U2OS cells with TRIM22/HIV-1 provirus, and 
used the resulting viral supernatants to infect the GHOST(3) X4/R5 reporter cell line 
(Figure 8). This provides a measurement of the infectious virus released, allowing a 
direct comparison of antiviral activity, regardless of the mechanism of action. As a result, 
this method holds an advantage over western blot, which measures total Gag protein, and 
cannot discriminate between infectious and non-infectious material. Importantly, 
expression of either isoform resulted in a dramatic decrease in the amount of virus 
released, regardless of cell-type. Furthermore, TRIM22β mediated restriction of virus 
release was approximately twice as effective as compared to TRIM22α, suggesting that 
their relative antiviral activity may be consistent between cell lines.  
Of note, the overall antiviral effect was much stronger in U2OS cells, suggesting 
that certain cell line specific differences may affect TRIM22 function. Similarly, Barr, et 
al. observed that TRIM22α expression in HOS cells had differential effects on 
intracellular Gag levels during proviral replication in HOS and U2OS cells. While 
intracellular Gag levels were unaffected by TRIM22α expression in HOS cells, they were 
dramatically reduced in U2OS cells [134]. It is possible this difference in intracellular 
Gag levels is merely a result of the reduced antiviral activity we observed in HOS cells, 
which may reflect cell type differences, such as the abundance of unknown cofactors, or 
an impact on some rate limiting step. On the other hand, we observed TRIM22α to 
restrict LTR transcription in U2OS cells, whereas Barr, et al. showed that TRIM22α alter 
trafficking of the Gag polyprotein in HOS cells. Therefore, it is possible that the 
difference in overall antiviral activity observed between HOS and U2OS cells may be the 
63 
 
 
 
result of separate mechanisms being utilized, which will provide an interesting avenue to 
follow up in future experiments. 
Both the TRIM22α and TRIM22β isoforms were capable of restricting 
transcription from the HIV-1 LTR in U2OS cells (Figure 9a). Although TRIM22β and 
the X82200 TRIM22 isoform have been shown to restrict LTR-mediated transcription in 
293T and Daudi cells, respectively [121, 144], this is the first evidence that TRIM22α can 
affect viral transcription. Interestingly, the effects on transcription are not unique to the 
HIV-1 LTR, as both isoforms also showed potent restriction of the CMV promoter in 
U2OS cells (Figure 9b). This result is in stark contrast to a previous report that observed 
TRIM22β to have no effect on a luciferase reporter gene under control of a CMV 
promoter in 293T cells [144]. An unknown TRIM22 isoform has also been shown to 
inhibit the activity of the hepatitis B virus core promoter in the hepatocellular carcinoma 
cell line HepG2, thus it is likely that TRIM22 is a broadly acting repressor of viral 
transcription, and potentially targets similar features among several promoters. As a 
result, we believe that the contradictory results obtained in U2OS and 293T cells may be 
a result of certain cell-specific differences, as discussed above. 
How TRIM22 restricts transcription from viral promoters is unknown but a 
fascinating problem for further study. It is intriguing that both isoforms can effectively 
repress transcription, despite the fact that TRIM22α is predominantly located in the 
cytoplasm, and TRIM22β is predominantly nuclear. It is possible that the two isoforms 
target the same protein/pathway or have entirely different targets, thus it will be 
important to further investigate and characterize the mechanisms of action. While we 
have yet to rule out that TRIM22 may also target HIV-1 RNA somehow, such as Rev-
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dependent RNA export, is important to note that the gag gene under control of the CMV 
promoter is both codon-optimized and Rev-independent. Taken together with the ability 
to restrict transcription from multiple viral promoters, it seems unlikely that RNA is a 
primary target. 
A recent report observed a significant decrease in LTR transcription was observed 
in TRIM22β-expressing cells during stimulation with phorbol 12-myristate 13-acetate 
(PMA) and ionomycin [144]. This stimulation activates the transcription factors AP-1 
and NFAT [203, 204], which are both important cis-acting elements present in the 
enhancer region of the HIV-1 LTR [12, 14]. Furthermore, AP-1 is important for optimal 
transcription from the HBV [205] and CMV [206] promoters, and NFAT was recently 
shown to be required for optimal reactivation of latent HIV-1 in CD4+ T cells [13]. One 
candidate model would be that TRIM22 interferes with one or more of the transcription 
factors required for optimal expression, such as AP-1 of NFAT. Furthermore, certain 
transcription factors, such as NFAT, reside in the cytoplasm until activated, which may 
explain why the cytoplasmic TRIM22α isoform is also capable of restricting 
transcription. It will be useful to identify if either TRIM22 isoform is capable of 
interacting with or altering the function of these transcription factors. PMA + ionomycin 
stimulation is also known to result in chromatin remodelling in the 5′ LTR of bovine 
leukemia virus [207], thus it is also possible that TRIM22 interferes with chromatin 
organization surrounding the HIV-1 LTR of the integrated provirus. 
It remains likely that different TRIM22 isoforms possess unique mechanisms of 
restriction in addition to a common ability to repress LTR dependent transcription. It is 
interesting to note that TRIM22β expression resulted in approximately twice the 
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restriction of TRIM22α in the virus release assay (Figure 8), and even more so in the 
qPCR assays (Figure 9); however, the two isoforms exhibited similar restriction profiles 
for the pGag-opt western blot (Figure 10). Only TRIM22α has previously been shown to 
alter Gag trafficking to the plasma membrane, thus it is possible TRIM22β possesses 
stronger effects on transcription and TRIM22α activity is stronger at the protein level. 
Surprisingly, TRIM22β restriction of the HIV-1 LTR was shown to be independent of its 
E3 ligase activity [144]. As this activity has been shown to be important for other 
TRIM22 antiviral activities, including restriction of the HBV core promoter [132, 134, 
146], it will be interesting to determine if E3 ligase activity is required for the antiviral 
activity that we observed. Additional studies will be useful to identify the mechanisms 
employed by these two TRIM22 isoforms, and to provide further insight into the potential 
impact of SNPs on TRIM22 functions. 
4.1 Limitations of this study 
One limitation to consider is that the majority of our experiments were primarily 
performed in the U2OS cell line. There is strong evidence to suggest that TRIM22 may 
possess different levels of activity or perform different actions, depending on which cell 
line is being investigated. While we observed both isoforms to restrict transcription from 
the HIV-1 LTR and CMV promoter in U2OS cells, previous studies observed TRIM22α 
to alter trafficking of the Gag polyprotein [134], and TRIM22β did not restrict 
transcription from the CMV promoter in 293T cells [144]. At this point it is unclear 
which factors may contribute to these differences, thus it will be important to repeat these 
experiments in additional cells lines. Furthermore, while these cell lines are useful study 
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tools, they are not biologically relevant to HIV-1 infection. Future experiments should 
include more relevant models, such as the Jurkat E6.1 T cell line or primary cells.  
While there appears to be striking differences between the TRIM22α and 
TRIM22β isoforms, this study was also limited by our use of only two TRIM22 isoforms. 
A total of 36 SNPs are currently known to exist in the trim22 gene, including 21 missense 
mutations, and 4 SNPs which result in different length proteins. Currently none of these 
SNPs have been investigated, thus it will be important to examine additional isoforms to 
better understand what effect these SNPs have on the functions of TRIM22. In addition, 
due to financial limitations, we were only able to investigate the prevalence of one SNP 
in a small number of cell lines; however, it will be essential to determine the prevalence 
of these SNPs in the population. 
4.2 Future directions 
The present study demonstrated that two unique TRIM22 isoforms are capable of 
restricting HIV-1 transcription and replication in the U2OS cell line. While we provided 
the first evidence that the TRIM22α isoform can restrict viral transcription, TRIM22α has 
previously been shown to alter Gag trafficking in HOS cells. Nevertheless, it is currently 
unknown if TRIM22α can also alter Gag trafficking in U2OS cells, or restrict LTR 
transcription in HOS cells. Determining which antiviral mechanisms are active in these 
cell lines may help to elucidate additional factors required for TRIM22-mediated 
restriction and explain the dramatic difference in antiviral potency between HOS and 
U2OS cells. 
In addition, all previous experiments demonstrating that TRIM22 can restrict LTR 
transcription have been performed using components from HIV-1 subtype B viruses. 
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While this is the best characterized form, subtype B only accounts for 12% of global 
infections, and observations obtained with this subtype may not be transferrable to other 
subtypes due to considerable differences in LTR composition, such as the number of 
NFκB response elements [10, 16]. It will be important to determine the capacity of 
TRIM22 to restrict transcription from the LTR of other HIV-1 subtypes. Furthermore, 
TRIM22 has also been shown to restrict transcription from the hepatitis B virus core 
promoter, thus it will be interesting to test the effect of TRIM22 on other viral promoters. 
This will not only help determine the breadth of TRIM22 activity, but these experiments 
may also help elucidate possible targets for TRIM22 based on common elements between 
viral promoters. 
In order to better understand the relationship between SNPs and TRIM22 
function, it will also be important to identify the TRIM22 isoforms used in previous 
studies, where possible, and to report all TRIM22 isoforms used in future experiments. It 
will also be useful to develop and characterize a panel of TRIM22 isoforms to determine 
which SNPs influence TRIM22 features, such as localization. Furthermore, experiments 
examining the trim22 haplotypes of both healthy and infected individuals will help 
determine the prevalence of each SNP and reveal any correlation between specific SNPs 
and HIV-1 disease progression. 
 
4.3 Conclusions 
In general, the study of how our immune system responds to HIV-1 infection has 
been a focus of researchers worldwide since AIDS was first recognized over 30 years 
ago. Understanding how a small percentage of individuals are naturally capable of 
68 
 
 
 
controlling HIV-1 replication remains one of the most sought after objectives towards the 
development of more effective therapies. While the contribution of cellular restriction 
factors in controlling HIV-1 infection is still controversial, evidence continues to build 
suggesting they do play a role. Furthermore, the effect that SNPs have on HIV-1 disease 
progression is becoming increasingly clear, and will be a necessary factor to consider in 
future investigations. 
Although findings on TRIM22 continue to suggest it is an important antiviral 
protein capable of restricting HIV-1 replication, much work remains to be done in order 
to fully ascertain how this protein functions. A balance between laboratory and clinical 
studies will help to elucidate the mechanisms responsible for these antiviral actions, as 
well as any potential effect TRIM22 may have on the progression of HIV-1 infection in 
vivo. Regardless, routine reporting of the TRIM22 isoforms used, along with the 
execution of studies directly comparing the actions of multiple isoforms will be a crucial 
step towards better understanding how SNPs may impact the function of TRIM22. 
Overall, increasing our knowledge of these host-pathogen interactions will allow for 
increased understanding of HIV-1 pathogenesis and the continuation of breakthroughs in 
HIV/AIDS treatment and prevention.  
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APPENDICES 
Appendix 1: Sequence information for the TRIM22α isoform. 
 
NUCLEOTIDE [CODING SEQUENCE: 1347 bp] 
atggatttctcagtaaaggtagacatagagaaggaggtgacctgccccatctgcctggagctcctgacagaacctctgagccta
gattgtggccacagcttctgccaagcctgcatcactgcaaagatcaaggagtcagtgatcatctcaagaggggaaagcagctgt
cctgtgtgtcagaccagattccagcctgggaacctccgacctaatcggcatctggccaacatagttgagagagtcaaagaggtc
aagatgagcccacaggaggggcagaagagagatgtctgtgagcaccatggaaaaaaactccagatcttctgtaaggaggatg
gaaaagtcatttgctgggtttgtgaactgtctcaggaacaccaaggtcaccaaacattccgcataaacgaggtggtcaaggaatg
tcaggaaaagctgcaggtagccctgcagaggctgataaaggaggatcaagaggctgagaagctggaagatgacatcagaca
agagagaaccgcctggaagatcgagagacagaagattctgaaagggttcaatgaaatgagagtcatcttggacaatgaggagc
agagagagctgcaaaagctggaggaaggtgaggtgaatgtgctggacaacctggcagcagctacagaccagctggtccagc
agaggcaggatgccagcacgctcatctcagatctccagcggaggttgacgggatcgtcagtagagatgctgcaggatgtgatt
gacgtcatgaaaaggagtgaaagctggacattgaagaagccaaaatctgtttccaagaaactaaagagtgtattccgagtacca
gatctgagtgggatgctgcaagttcttaaagagctgacagatgtccagtactactgggtggacgtgatgctgaatccaggcagtg
ccacttcgaatgttgctatttctgtggatcagagacaagtgaaaactgtacgcacctgcacatttaagaattcaaatccatgtgatttt
tctgcttttggtgtcttcggctgccaatatttctcttcggggaaatattactgggaagtagatgtgtctggaaagattgcctggatcct
gggcgtacacagtaaaataagtagtctgaataaaaggaagagctctgggtttgcttttgatccaagtgtaaattattcaaaagtttac
tccagatatagacctcaatatggctactgggttataggattacagaatacatgtgaatataatgcttttgaggactcctcctcttctgat
cccaaggttttgactctctttatggctgtgcctccctgtcgtattggggttttcctagctcgagcatgcatctag 
 
PROTEIN (448 aa) 
MDFSVKVDIEKEVTCPICLELLTEPLSLDCGHSFCQACITAKIKESVIISRGESSCPV
CQTRFQPGNLRPNRHLANIVERVKEVKMSPQEGQKRDVCEHHGKKLQIFCKEDG
KVICWVCELSQEHQGHQTFRINEVVKECQEKLQVALQRLIKEDQEAEKLEDDIR
QERTAWKIERQKILKGFNEMRVILDNEEQRELQKLEEGEVNVLDNLAAATDQLV
QQRQDASTLISDLQRRLTGSSVEMLQDVIDVMKRSESWTLKKPKSVSKKLKSVF
RVPDLSGMLQVLKELTDVQYYWVDVMLNPGSATSNVAISVDQRQVKTVRTCTF
KNSNPCDFSAFGVFGCQYFSSGKYYWEVDVSGKIAWILGVHSKISSLNKRKSSGF
AFDPSVNYSKVYSRYRPQYGYWVIGLQNTCEYNAFEDSSSSDPKVLTLFMAVPP
CRIGVFLARACI 
 
NOTE 
Underlined sequence is from the pcDNA3.1 plasmid. 
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Appendix 2: Sequence information for the TRIM22β isoform. 
 
ACCESSION BC035582 
 
NUCLEOTIDE [CODING SEQUENCE: 1497 bp] 
atggatttctcagtaaaggtagacatagagaaggaggtgacctgccccatctgcctggagctcctgacagaacctctgagccta
gattgtggccacagcttctgccaagcctgcatcactgcaaagatcaaggagtcagtgatcatctcaagaggggaaagcagctgt
cctgtgtgtcagaccagattccagcctgggaacctccgacctaatcggcatctggccaacatagttgagagagtcaaagaggtc
aagatgagcccacaggaggggcagaagagagatgtctgtgagcaccatggaaaaaaactccagatcttctgtaaggaggatg
gaaaagtcatttgctgggtttgtgaactgtctcaggaacaccaaggtcaccaaacattccgcataaacgaggtggtcaaggaatg
tcaggaaaagctgcaggtagccctgcagaggctgataaaggaggatcaagaggctgagaagctggaagatgacatcagaca
agagagaaccgcctggaagaattatatccagatcgagagacagaagattctgaaagggttcaatgaaatgagagtcatcttgga
caatgaggagcagagagagctgcaaaagctggaggaaggtgaggtgaatgtgctggacaacctggcagcagctacagacca
gctggtccagcagaggcaggatgccagcacgctcatctcagatctccagcggaggttgaggggatcgtcagtagagatgctgc
aggatgtgattgacgtcatgaaaaggagtgaaagctggacattgaagaagccaaaatctgtttccaagaaactaaagagtgtatt
ccgagtaccagatctgagtgggatgctgcaagttcttaaagagctgacagatgtccagtactactgggtggacgtgatgctgaat
ccaggcagtgccacttcgaatgttgctatttctgtggatcagagacaagtgaaaactgtacgcacctgcacatttaagaattcaaat
ccatgtgatttttctgcttttggtgtcttcggctgccaatatttctcttcggggaaatattactgggaagtagatgtgtctggaaagattg
cctggatcctgggcgtacacagtaaaataagtagtctgaataaaaggaagagctctgggtttgcttttgatccaagtgtaaattattc
aaaagtttactccagatatagacctcaatatggctactgggttataggattacagaatacatgtgaatataatgcttttgaggactcct
cctcttctgatcccaaggttttgactctctttatggctgtgcctccctgtcgtattggggttttcctagactatgaggcaggcattgtctc
atttttcaatgtcacaaaccacggagcactcatctacaagttctctggatgtcgcttttctcgacctgcttatccgtatttcaatccttgg
aactgcctagtccccatgactgtgtgcccaccgagctcctga 
 
PROTEIN (498 aa) 
MDFSVKVDIEKEVTCPICLELLTEPLSLDCGHSFCQACITAKIKESVIISRGESSCPV
CQTRFQPGNLRPNRHLANIVERVKEVKMSPQEGQKRDVCEHHGKKLQIFCKEDG
KVICWVCELSQEHQGHQTFRINEVVKECQEKLQVALQRLIKEDQEAEKLEDDIR
QERTAWKNYIQIERQKILKGFNEMRVILDNEEQRELQKLEEGEVNVLDNLAAAT
DQLVQQRQDASTLISDLQRRLRGSSVEMLQDVIDVMKRSESWTLKKPKSVSKKL
KSVFRVPDLSGMLQVLKELTDVQYYWVDVMLNPGSATSNVAISVDQRQVKTVR
TCTFKNSNPCDFSAFGVFGCQYFSSGKYYWEVDVSGKIAWILGVHSKISSLNKRK
SSGFAFDPSVNYSKVYSRYRPQYGYWVIGLQNTCEYNAFEDSSSSDPKVLTLFM
AVPPCRIGVFLDYEAGIVSFFNVTNHGALIYKFSGCRFSRPAYPYFNPWNCLVPM
TVCPPSS
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Appendix 3: Ethics approval notice for use of human subjects. 
 
(Signature removed for publication) 
 
(Contact information removed for publication) 
  Contact 
 
(Contact information removed for publication) 
89 
 
 
 
CURRICULUM VITAE  
Name:   Clayton Hattlmann 
 
Post-secondary  The University of Western Ontario, MSc. 2009-2012 
Education and  London, Ontario, Canada 
Degrees:    
The University of Western Ontario, BMSc. 2004-2009 
London, Ontario, Canada 
 
Honours and   Schulich Graduate Scholarship  2009-2011 
Awards:    
   Schulich Grad. Enhancement Scholarship 2009-2011 
 
   Dean‟s Honor List    2008-2009 
 
Undergraduate Entrance Scholarship  2004-2005 
 
Related Work  Teaching Assistant    2011 
Experience   The University of Western Ontario 
 
Undergraduate Research Student  2008-2009 
The University of Western Ontario 
 
Internship Student    2007-2008 
Sanofi Pasteur 
Publications: 
Woods, M.W., Kelly
+
, J.N., Hattlmann
+
, C.J., Xu, L.S., Tong, J.G.K., Smiley, J.R., 
Barr, S.D. 2011. Human HERC5 restricts an early stage of HIV-1 assembly by a 
mechanism correlating with the ISGylation of Gag. Retrovirology. 8: 95. (
+
 
contributed equally) 
Ha, S., Park, S., Hattlmann, C.J., Barr, S.D., Kim, S.O. 2011. Inhibition or deficiency of 
cathepsin B leads to defects in HIV-1 Gag pseudoparticle release in macrophages 
and HEK293T cells. Antiviral Research. 93(1):175-84. 
Kelly, J., Tong, J., Hattlmann, C., Woods, M., Barr, S.D. (2011) ISBN 978-953-307-
665-2. Book Title: HIV and AIDS – Updates on Biology, Immunology, 
Epidemiology and Treatment Strategies. Chapter Title: “Cellular Restriction 
Factors: Can We Exploit the Body‟s Natural Antiviral Proteins to Combat 
HIV/AIDS?” (Invited Book Chapter) 
